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Abstract: Dibenzyl butyrolactone lignans are well known for their excellent biological properties,
particularly for their notable anti-proliferative activities. Herein we report a novel, efficient,
convergent synthesis of dibenzyl butyrolactone lignans utilizing the acyl-Claisen rearrangement to
stereoselectively prepare a key intermediate. The reported synthetic route enables the modification of
these lignans to give rise to 5-hydroxymethyl derivatives of these lignans. The biological activities of
these analogues were assessed, with derivatives showing an excellent cytotoxic profile which resulted
in programmed cell death of Jurkat T-leukemia cells with less than 2% of the incubated cells entering
a necrotic cell death pathway.
Keywords: lignans; dibenzyl butyrolactones; anti-proliferative; acyl-Claisen; stereoselective synthesis
1. Introduction
Dibenzyl butyrolactone lignans 1 are a class of lignans which have been reported to exhibit
a range of biological activities, including, but not limited to neuroprotective [1], anti-cancer [2,3],
anti-inflammatory [2,4], and anti-aging effects (see Figure 1) [5]. Perhaps the most notable of these
biological properties is their reported potent anti-proliferative activities; examples of this class include
(−)-matairesinol 2 and (−)-arctigenin 3 which, along with their synthesized derivatives, have been
shown to exhibit excellent activity against various cancer cell lines, including pancreatic, breast,
endometrial, colorectal, lung, and bladder cancers [6–12].
Owing to their anti-cancer properties and their classification as drug-like compounds [13]
extensive work has gone into the study of these compounds and their related analogues to explore
and establish structure–activity relationships and the possible use of these lignans as lead compounds
for therapeutics. Whilst previous work has explored the synthesis of these lignans and analogues
thereof [14–16], mainly focusing on changing the substituents on the aryl rings [17], one area that has
not been extensively investigated is the synthesis of C-5 substituted analogues of these butyrolactone
lignans, represented by 4.
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Figure 1. General structures of butyrolactone lignan 1, natural dibenzylbutyrolactone lignans, (-)-
matairesinol 2 and (-)-artigenin 3, and 5-hydroxymethyl analogues 4. 
We have previously shown that the acyl-Claisen rearrangement can be used to prepare 
disubstituted morpholine pentenamides 5 with high diastereoselectivity at the C-3 and C-4 positions 
which correspond to the benzyl groups in the lactone scaffold (Figure 2) [18–22]. Furthermore, in our 
efforts to a prepare a number of different lignan scaffolds [18–36], we have used amides such as 5 to 
prepare compounds including tetrahydrofuran lignans (e.g., galbelgin 6), aryltetralins (e.g., 
ovafolinin 7) and aryl dihydronaphthalene lignans (e.g., (-)-pycananthuligene B 8). 
 
Figure 2. Use of amide 5, the product of an acyl-Claisen rearrangement to access a number of lignan 
scaffolds and natural products 6–8. 
We wished to explore the usage of this methodology to synthesise butyrolactone lignans, as well 
as probe the effect of adding a substituent at the C-5 position on the biological activity. The route 
would be convergent and modular, allowing for simple modification of aromatic groups resulting in 
the synthesis of a number of analogues.2. Results and Discussion 
In order to utilise the acyl-Claisen rearrangement to prepare the desired lactones, the 
corresponding allylic morpholines and acid chlorides first needed to be synthesised. Allylic 
morpholines 9a and 9b were synthesised in five steps from 4-allyl-1,2-dimethoxybenzene 10 and 
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We wished to explore the usage of this methodology to synthesise butyrolactone lignans, as well
as probe the effect of adding a substituent at the C-5 position on the biological activity. The route
would be convergent and modular, allowing for simple modification of aromatic groups resulting in
the synthesis of a number of analogues.
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2. Results and Discussion
In order to utilise the acyl-Claisen rearrangement to prepare the desired lactones,
the corresponding allylic morpholines and acid chlorides first needed to be synthesised. Allylic
morpholines 9a and 9b were synthesised in five steps from 4-allyl-1,2-dimethoxybenzene 10 and
safrole 11 (Scheme 1), respectively. Firstly, allylic benzenes 10 and 11 were dihydroxylated
using catalytic osmium tetroxide giving 12 and 13, followed by periodate cleavage to give
aldehydes 14 and 15. Aldehydes 14 and 15 were immediately used in a Wittig reaction with
(carbethoxymethylene)-triphenylphosphorane to exclusively give the E-isomer of α,β-unsaturated
esters 16 and 17, in 55% and 56% yields, respectively, over three steps. The esters 16 and 17 were then
reduced to allylic alcohols 18 and 19 using di-iso-butyl aluminium hydride (DIBAL-H) in excellent
yields. Alcohols 18 and 19 were then converted to the corresponding allylic morpholines 9a and 9b,
by first generating a mesylate in situ, which then underwent substitution to give allylic morpholines
9a and 9b.
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il le benzaldehydes—piperonal 20, 3,4,5-trimethoxybenzaldehyde 21 and vanillin 22 (Schem 2).
Benzaldehydes 20–22 first underwent a Wittig reaction with (carbethoxymethylene)triph nylphosphorane
to give α,β-unsaturated esters 23–25 which w re then hydrogenated using Pd on Carbon (10% w/w),
giving saturated esters 26–28 in 88–94 yield over two steps. The phenol in 2 was protected as the
benzyl ether, 29, in 83% yield. Esters 26, 27, and 29 were hydrolysed using NaOH in methanol/water
to the corresponding carboxylic acids 30, 31, and 32, respectively, in 94–99% yields. Finally, chlori ation
of acids 30–32, along with commercially available 3,4-dimethoxyphenyl propionic acid 33, using ox lyl
chloride gave acid chlorides 34a–d in quantitative yields.
Acyl-Claisen rearrangements were undertaken using two allylic morpholines 9a and 9b which
were reacted individually with the four acid chlorides 34a–d, using TiCl4·2THF as the Lewis acid,
providing eight morpholine amides 35aa–bd in 42–95% yields. All amides 35aa–bd were obtained
as single diastereomers with a syn-configuration between the C-2 and C-3 substituents (Scheme 3).
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All amides 35aa–bd then underwent dihydroxylation using osmium tetroxide and N-methylporpholine
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In all cases it was observed that only the 3,4-trans-4,5-trans-lactone was obtained. This configuration
was confirmed through NOESY NMR analysis, depicted in Figure 3 with 4bb. We propose that only
this isomer was obtained due to the preferential cyclisation of the 3,4-anti diol 36, leaving the polar
uncyclised 3,4-syn diols 37 which were difficult to isolate. Upon dihydroxylation of amide 35bb at
a larger scale and following isolation of lactone 4bb by column chromatography, a small sample of the
corresponding uncyclised diol 37 was able to be isolated. This diol 37 was subsequently cyclised using
2 M H2SO4 in methanol to give the corresponding C-5 epimer, epi-4bb, confirming this hypothesis
(Scheme 4).
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Finally, to deprotect the benzyl-protected lactones 4ad and 4bd to their respective alcohols, they
were subjected to hydrogenolysis to give 4ae and 4be in excellent yields. Transformation of C-5
hydroxymethyl analogues 4 into dibenzylbutryolactone lignans 1 was achieved via reduction using
LiAlH4, to the corresponding triols 38aa–bd, followed by periodate cleavage, forming lactols 39aa–bd.
These lactols 39aa–bd were then oxidised using Fetizon’s reagent [37,38] to give racemic samples of
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dibenzyl butyrolactone lignans 1aa–bd, including known natural products arcitin 1aa, bursehernin
1ab, (3R*,4R*)-3-(3′′,4′′-dimethoxybenzyl)-4-(3′,4′,5′-trimethoxybenzyl)dihydrofuran-2(3H)-one 1ac,
kusunokinin 1ba, hinokinin 1bb, and isoyatein 1bc. Additionally, phenolic lignans, buplerol 1ae, and
haplomyrfolin 1be were produced by the debenzylation of 1ad and 1bd, respectively.Molecules 2018, 23, x FOR PEER REVIEW  7 of 26 
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Several of the synthesised co pounds ere then tested for their anti- icrobial and cytotoxic
activities. All tested compounds were found to be inactive against Staphlycoccus aureus and Escherichia.
coli, showing no to little antimicrobial activity, while the compounds were shown to exhibit
antiproliferative effects against Jurkat T-leukaemia cells, while also showing effects on cell cycle
progression (Figure 4). While the synthesised naturally-occurring dibenzyl butyrolactones, arcitin 1aa,
bursehernin 1ab, and (3R*,4R*)-3-(3′′,4′′-dimethoxybenzyl)-4-(3′,4′,5′-trimethoxybenzyl)dihydrofuran-
2(3H)-one 1ac, boasted the best activities, 5-hydroxymethyl analogue 4bb had similar potency.
Compound 4bb was shown to have the best activity of all of the 5-hydroxymethyl analogues tested,
inducing apoptosis, evidenced by the presence of cells in the early and predominantly in the late
apoptotic cell cycle (Figure 4). Additionally the compounds demonstrated an effect on cell cycle
progression. A significantly greater number of 4N cells were present following treatment ith
compound 4bb in particular causing a significant increase in 4N cells (Figure 4D,E). During the
cell cycle, DNA is replicated in the S-phase, going from 2N in G1, to 4N by the end of this phase.
The DNA content in cells then remains at 4N during G2 and M phases, before cytokinesis at the
M-phase. The observation that there was in increase in 4N cells indicates that it is likely these cells
have arrested in G2/M and will not re-enter next G1-phase after this mitotic slippage. This is in-line
with published cell cycle data follo ing treatment with other lignans [39,40]. Furthermore, our
compounds showed minimal levels of necrosis, less than 2% (except 4ba with 7%), suggesting that
the cells are in fact entering programmed cell death cycles, which is consi ered the most effective and
non-inflammatory mechanism of cancer-cell death.
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re io sl - ex lore 5- rox et l eri ati es 4 of these natural products. e iolo ical
acti ities of t is e set of eri ati es ere assesse , it o e eri ati e i artic lar, 4 , s o i g
a s erior c totoxic rofile and resulting in cell cycle arrest and progra med cell death of Jurkat
T-leukaemia cells with less than 2% of the incubated cells entering a necrotic cell death pathway.
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leukaemia cells after incubation with 100 µM 4bb for 24 h followed by labelling with annexin 
V/propidium iodide and analysis using flow cytometry. Cells in the bottom-left quadrant represent 
viable cells, bottom-right quadrant are positive for annexin V and are in early apoptosis, top-right 
quadrant are double positive for annexin V and propidium iodide and are in late apoptosis, and top-
left quadrant are only positive for propidium iodide and are undergoing necrosis. C: Negative control 
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unsynchronized cells incubated in the presence of 100 µM 4bb or E: vehicle for 24 h. DNA content of 
Figure 4. (A) Cell survival (by a measure of metabolic activity) of Jurkat T-cell leukaemia cells incubated
with 100 µM of lignans and lignan analogues for 48 h. The data represents means of triplicate
experiments and is shown as means ± SEM (n = 3). The positive control (not shown) had a growth
of 100%. Significance of the comp und activity compared to the control is expre s d: (*) p-value
<0.05; (**) p-value <0.01; (***) p-value <0.001. (B) Dotplot showing he viability of Jurkat T-leukaemia
cells aft r incubation wi h 100 µM 4bb for 24 h followed by labelling with ann xi V/propidium
iodide and analysis using flow cytometry. Cells in the bottom-left quadrant r present viable cells,
bottom-right quadrant are positive for annexin V and are in early apoptosis, top-right quadrant are
double positive for annexin V and propidium iodide and are in late apoptosis, and top-left quadrant
are only positive for propidium iodide and are undergoing necrosis. (C) Negative control showing the
viability of vehicle-(DMSO) treated Jurkat T-leukaemia cells. (D) Cell cycle analysis of unsynchronized
cells incubated in the presence of 100 µM 4bb or E: vehicle for 24 h. DNA content of the cells was
determined by flow cytometry. Percentage of cells in each stage of the cell cycle (average of three
replicates ± SD is reported).
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3. Experimental Section
3.1. General Methods
All reactions were carried out with oven-dried glassware and under a nitrogen atmosphere in
dry, freshly distilled solvents unless otherwise noted. Diisopropylethylamine was distilled from CaH2
and stored over activated 4Å molecular sieves. All melting points for solid compounds, given in
degrees Celsius (◦C), were measured using a Reicher–Kofler block and are uncorrected. Infrared (IR)
spectra were recorded using a Perkin Elmer Spectrum1000 FT-IR spectrometer. The NMR spectra were
recorded on a 400 MHz spectrometer. Chemical shifts are reported relative to the solvent peak of
chloroform (δ 7.26 for 1H and δ 77.16 ± 0.06 for 13C). The 1H-NMR data was reported as position (δ),
relative integral, multiplicity (s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet
of doublets; dt, doublet of triplets; dq, doublet of quartets; t, triplet; td, triplet of doublets; q, quartet;
m, multiplet), coupling constant (J, Hz), and the assignment of the atom. The 13C-NMR data were
reported as position (δ) and assignment of the atom. The NMR assignments were performed using
COSY, HSQC and HMBC experiments. High-resolution mass spectroscopy (HRMS) was carried out by
electrospray ionization (ESI) on a MicroTOF-Q mass spectrometer. Fetizon’s reagent was prepared
following a literature procedure [41]. Unless noted, chemical reagents were used as purchased.
3.2. Synthetic Methods
3.2.1. General Procedure A: Acyl-Claisen
To a stirred suspension of TiCl4·2THF (1 mmol) in CH2Cl2 (5 mL), under an atmosphere of
nitrogen, was added a solution of allylic morpholine (1 mmol) in CH2Cl2 (2.5 mL) followed by
dropwise addition of iPr2NEt (1.5 mmol). After stirring for 10 min a solution of acid chloride (1.2 mmol)
in CH2Cl2 (2.5 mL) was added dropwise and the resultant mixture stirred for the specified time.
The reaction mixture was quenched with aqueous NaOH (12 mL, 1 M) and the aqueous phase extracted
with CH2Cl2 (3 × 10 mL). The combined organic extracts were washed with brine (6 mL), dried
(MgSO4), the solvent removed in vacuo and the crude product purified by column chromatography.
3.2.2. General Procedure B: Dihydroxylation
To a stirred solution of morpholine pentenamide (1 mmol) in tBuOH/H2O (1:1, 20 mL) or
tBuOH/H2O/THF (1:1:1, 30 mL) was added NMO (3 mmol). A solution of OsO4 (0.08 mmol, 2.5%
w/v in tBuOH) was then added dropwise and the resultant mixture stirred for the specified time.
The mixture was quenched with saturated aqueous Na2SO3 (30 mL) and stirred for a further 1 h.
The aqueous phase was extracted with ethyl acetate (3× 20 mL), the combined organic extracts washed
with aqueous KOH (5 mL, 1 M), dried (MgSO4), the solvent removed in vacuo and the crude product
purified by column chromatography.
3.2.3. General Procedure C: Lithium Aluminum Hydride Reduction
To a stirred suspension of LiAlH4 (1.4 mmol) in THF (10 mL), under an atmosphere of nitrogen
at 0 ◦C, was added a solution of lactone (1 mmol) in THF (10 mL) and the mixture stirred for the
specified time. After warming to room temperature, the mixture was quenched with the addition of
water (30 mL) and the aqueous phase extracted with ethyl acetate (3 × 40 mL). The combined organic
extracts were washed with brine (25 mL), dried (MgSO4), and the solvent removed in vacuo.
3.2.4. General Procedure D: Periodate Cleavage
To a stirred solution of triol (1 mmol) in MeOH/H2O (3:1, 50 mL) was added NaIO4 (1.2 mmol)
and the resultant mixture stirred for the specified time. The reaction mixture was quenched with brine
(40 mL) and extracted with ethyl acetate (3 × 80 mL). The organic layers were combined, washed with
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water (2 × 40 mL), dried (MgSO4), and solvent removed in vacuo to give the crude product which was
purified by column chromatography if necessary.
3.2.5. General Procedure E: Fétizon’s Oxidation
To a stirred solution of lactol (1 mmol) in toluene (60 mL), under an atmosphere of nitrogen, was
added Fétizon′s reagent (2 mmol) and heated at reflux for the specified time. The reaction mixture
was allowed to cool and filtered, the solvent removed in vacuo and the crude product purified by
column chromatography.
3.2.6. General Procedure F: Benzyl Deprotection
To a stirred solution of benzyl ether (1 mmol) in MeOH (30 mL) was added 10% palladium
on carbon (20% w/w) and the resultant mixture stirred under and atmosphere of hydrogen for the
specified time. The reaction mixture was filtered through celite, washed with methanol (3 × 20 mL),
the solvent removed in vacuo and the crude product purified by column chromatography if necessary.
(E)-Ethyl 4-(3′,4′-dimethoxyphenyl)but-2-enoate (16). To a stirred solution of NMO (7.9 g, 67.3 mmol) in
H2O/tBuOH (1:1, 80 mL) was added 4-allyl-1,2-dimethoxybenzene 10 (3.86 mL, 22.4 mmol). A solution
of OsO4 (0.6 mL, 0.059 mmol, 2.5% w/v in tBuOH) was then added dropwise and the resulting mixture
stirred at room temperature for 4 days. The mixture was then quenched with saturated aqueous
Na2SO3 (100 mL) and stirred for 1 h. The mixture was extracted with ethyl acetate (3 × 50 mL),
the organic layers combined, washed with aqueous KOH (1 M, 20 mL), and dried (MgSO4). Solvent
was removed in vacuo to give 12 (4.8 g, quant.) as a white solid which was used without further
purification. To a stirred solution of diol 12 (4.8 g, 22.8 mmol) in methanol/H2O (3:1, 100 mL) was
added NaIO4 (5.9 g, 27.4 mmol) and stirred for 30 min. The reaction mixture was then quenched with
addition of brine (50 mL) and extracted with ethyl acetate (3 × 40 mL). The organic extracts were
combined, washed with water (2 × 20 mL), and dried (MgSO4). Solvent was removed in vacuo to
give 14 (2.68 g, 65%) as a pale-yellow oil which was used without further purification. To a stirred
solution of 2-(3,4-dimethoxyphenyl)acetaldehyde 14 (2.68 g, 14.8 mmol) in CH2Cl2 (100 mL), under
an atmosphere of nitrogen, was added (carbethoxymethylene)triphenylphosphorane (5.7 g, 16.3 mmol)
and the resulting mixture stirred for 16 h. Solvent was removed in vacuo and the crude product
purified by column chromatography (3:1, hexanes, ethyl acetate) to give the title compound 16 (3.13 g,
84%) as a colourless oil. Rf = 0.56 (2:1 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.27 (3H, t,
J = 7.2 Hz, 1-OCH2CH3), 3.45 (2H, dd, J = 1.5, 6.7 Hz, 4-H), 3.86 (6H, s, 3′, 4′-H), 4.17 (2H, q, J = 7.2 Hz,
1-OCH2CH3), 5.80 (1H, td, J = 1.6, 15.5 Hz, 2-H), 6.67 (1H, d, J = 1.9 Hz, 2′-H), 6.71 (1H, dd, J = 1.9,
8.1 Hz, 6′-H), 6.81 (1H, d, J = 8.1 Hz, 5′-H), 7.07 (1H, td, J = 6.7, 15.5 Hz, 3-H). δC (100 MHz; CDCl3)
14.3 (1-OCH2CH3), 38.1 (C-4), 55.9, 56.0 (3′, 4′-OCH3), 60.3 (1-OCH2CH3), 111.5 (C-5′), 112.1 (C-2′),
120.8 (C-6′), 122.2 (C-2), 130.2 (C-1′), 147.6 (C-3), 147.9 (C-4′), 149.1 (C-3′), 166.6 (C-1). Values are in
agreement with literature data [42].
(E)-4-(3′,4′-Dimethoxyphenyl)but-2-en-1-ol (18). To a stirred solution of ester 16 (1.0 g, 4.0 mmol) in
CH2Cl2 (20 mL), under an atmosphere of nitrogen at −78 ◦C, was added DIBAL (12 mL, 1 M in
cyclohexane) and the resulting mixture stirred for 10 min. The reaction mixture was quenched with
addition of 2 M HCl until gas evolution ceased, the organic phase separated and the aqueous phase
further extracted with CH2Cl2 (3 × 10 mL). The organic layers were combined then washed with water
(10 mL) and dried (MgSO4). Solvent was removed in vacuo and the crude product purified by column
chromatography (1:1 hexanes, ethyl acetate) to give the title compound 18 (0.76 g, 92%) as a colourless
oil. Rf = 0.18 (2:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 3.30 (2H, d, J = 6.6 Hz, 4-H), 3.82 (3H, s,
4′-OCH3), 3.83 (3H, s, 3′-OCH3), 4.08 (2H, d, J = 5.6 Hz, 1-H), 5.64–5.69 (1H, m, 2-H), 5.78–5.83 (1H, m,
3-H), 6.68 (1H, s, 2′-H), 6.69 (1H, d, J = 8.0 Hz, 6′-H), 6.77 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3)
38.2 (C-4), 55.8 and 55.9 (3′ and 4′-OCH3), 63.3 (C-1), 111.4 (C-5′), 112.0 (C-2′), 120.4 (C-6′), 130.2 (C-2),
131.6 (C-3), 132.7 (C-1′), 147.4 (C-4′), 148.9 (C-3′). IR: νMAX (film)/cm-1; 3391 (broad), 2933, 2835, 1591,
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1512, 1463, 1417, 1258, 1232, 1137, 1025, 971, 852, 806, 762. HRMS (ESI+) Found [M + Na]+ 231.0995;
C12H16NaO3 requires 231.0992.
(E)-4-(4-(3′,4′-Dimethoxyphenyl)but-2-en-1-yl)morpholine (9a). To a stirred solution of alcohol 18 (0.73 g,
3.5 mmol) in CH2Cl2 (20 mL), under an atmosphere of nitrogen at 0 ◦C, was added Et3N (1.5 mL,
10.5 mmol) and stirred for 5 min. MsCl (0.48 mL, 4.2 mmol) was added and stirred for 10 min.
Morpholine (0.50 mL, 5.3 mmol) was added and the mixture brought to room temperature and stirred
for 2 h. Saturated aqueous NaHCO3 (20 mL) and water (4 mL) was then added and the aqueous layer
further extracted with CH2Cl2 (3 × 20 mL). The organic layers were then combined, dried (MgSO4)
and the solvent removed in vacuo. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 9a (0.60 g, 62%) as a colourless oil. Rf = 0.31
(1:2 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.41–2.44 (4H, m, O(CH2CH2)2N), 2.96 (2H, d, J =
6.8 Hz, 1-H), 3.30 (2H, d, J = 6.7 Hz, 4-H), 3.68–3.71 (4H, m, O(CH2CH2)2N), 3.83 (6H, s, 3′, 4′-OCH3),
5.52–5.57 (1H, m, 3-H), 5.71–5.78 (1H, m, 2-H), 6.67–6.70 (2H, m, 2′ and 6′-H), 6.78 (1H, d, J = 7.9 Hz,
5′-H). δC (100 MHz; CDCl3) 38.5 (C-4), 53.6 (O(CH2CH2)2N), 55.8, 56.0 (3′, 4′-OCH3), 61.1 (C-1), 67.0
(O(CH2CH2)2N), 111.4 (C-5′), 111.9 (C-2′), 120.3 (C-6′), 127.1 (C-3), 132.8 (C-1′), 133.8 (C-2), 147.5 (C-4′),
149.0 (C-3′). IR: νMAX (film)/cm−1; 2934, 2851, 1591, 1453, 1260, 1138, 1028, 976, 864, 805, 763. HRMS
(ESI+) Found [M + H]+ 278.1762; C16H24NO3 requires 278.1751.
(E)-Ethyl 4-(3′,4′-methylenedioxyphenyl)but-2-enoate (17). To a stirred solution of NMO (8.67 g, 74.0 mmol)
in H2O/tBuOH (1:1, 80 mL) was added safrole 11 (4.0 mL, 27 mmol). A solution of OsO4 (0.75 mL,
0.074 mmol, 2.5% w/v in tBuOH) was added dropwise and the resultant mixture stirred at room
temperature for 17 h. The reaction mixture was quenched with saturated aqueous Na2SO3 (100 mL)
and stirred for 1 h. The mixture was extracted with ethyl acetate (3 × 50 mL), the organic layers were
combined, washed with aqueous KOH (1 M, 20 mL) and dried (MgSO4). Solvent was removed in
vacuo to give diol 13 (5.2 g, quant.) as a white solid which was used without further purification.
To a stirred solution of diol 13 (5.2 g, 27 mmol) in methanol/H2O (3:1, 100 mL) was added NaIO4
(6.8 g, 32 mmol) and stirred for 2 h. The mixture was then quenched with addition of brine (50 mL)
and extracted with ethyl acetate (3 × 50 mL). The organic extracts were combined, washed with water
(2 × 20 mL), brine (10 mL), and dried (MgSO4). Solvent was removed in vacuo to give aldehyde
15 (4.4 g, quant.) as a yellow oil which was used without further purification. To a stirred solution
of 2-(3,4-methylenedioxyphenyl)acetaldehyde 15 (4.4 g, 27 mmol) in CH2Cl2 (50 mL), under an
atmosphere of nitrogen, was added (carbethoxymethylene)triphenylphosphorane (10.4 g, 30 mmol)
and the resulting mixture stirred for 16 h. Solvent was removed in vacuo and the crude product
purified by column chromatography (19:1, hexanes, ethyl acetate) to give the title compound 17 (3.54 g,
56%) as a colourless oil. Rf = 0.73 (2:1 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.27 (3H, t,
J = 7.2 Hz, 1-OCH2CH3), 3.42 (2H, dd, J = 6.6, 1.6 Hz, 4-H), 4.17 (2H, q, J = 7.2 Hz, 1-OCH2CH3), 5.78
(1H, dt, J = 15.5, 1.6 Hz, 2-H), 5.93 (2H, s, OCH2O), 6.61 (1H, dd, J = 8.0, 2.0 Hz, 6′-H), 6.64 (1H, d, J =
2.0 Hz, 2′-H), 6.74 (1H, d, J = 8.0 Hz, 5′-H), 7.04 (1H, dt, J = 15.5, 6.6 Hz, 3-H). δC (100 MHz; CDCl3)
14.4 (1-OCH2CH3), 38.2 (C-4), 60.4 (1-OCH2CH3), 101.1 (OCH2O), 108.5 (C-5′), 109.4 (C-2′), 121.9 (C-6′),
122.4 (C-2), 131.5 (C-1′), 146.5 (C-4′), 147.5 (C-3), 148.0 (C-3′), 166.6 (C-1). Values are in agreement with
literature data [43].
(E)-4-(3′,4′-Methylenedioxyphenyl)but-2-en-1-ol (19). To a stirred solution of ester 17 (3.2 g, 13.7 mmol)
in toluene (100 mL), under an atmosphere of nitrogen at −10 ◦C, was added DIBAL (30 mL, 1 M
in toluene) and the resultant mixture stirred for 10 min. The reaction mixture was quenched with
addition of 2 M HCl until gas evolution ceased, the organic layer was separated and the aqueous phase
further extracted with CH2Cl2 (3 × 50 mL). The organic layers were combined, washed with brine (30
mL) and dried (MgSO4). Solvent was removed in vacuo and the crude product purified by column
chromatography (3:1 hexanes, ethyl acetate) to give the title compound 19 (2.59 g, 98%) as a pale yellow
oil. Rf = 0.42 (hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.41 (1H, br s, 1-OH), 3.30 (2H, d, J = 6.6
Hz, 4-H), 4.12 (2H, br d, J = 4.5 Hz, 1-H), 5.64–5.72 (1H, m, 2-H), 5.77–5.85 (1H, m, 3-H), 5.92 (2H, s,
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OCH2O), 6.63 (1H, dd, J = 7.9, 1.9 Hz, 6′-H), 6.67 (1H, d, J = 1.9 Hz, 2′-H), 6.73 (1H, d, 7.9 Hz, 5′-H). δC
(100 MHz; CDCl3) 38.4 (C-4), 63.6 (C-1), 101.0 (OCH2O), 108.3 (C-5′), 109.2 (C-2′), 121.4 (C-6′), 130.4,
131.8 (C-2, 3), 133.9 (C-1′), 146.0, 147.8 (C-3′, 4′). Values are in agreement with literature data [43].
(E)-4-(4-(3′,4′-Methylenedioxyphenyl)but-2-en-1-yl)morpholine (9b). To a stirred solution of alcohol 19
(1.66 g, 8.6 mmol) in CH2Cl2 (15 mL), under an atmosphere of nitrogen at 0 ◦C, was added Et3N
(3.6 mL, 25.9 mmol) and stirred for 5 min. MsCl (1.2 mL, 10.4 mmol) was added and stirred for 10 min.
Morpholine (1.3 mL, 13.8 mmol) was added and the mixture brought to room temperature and stirred
for 18 h. Saturated aqueous NaHCO3 (25 mL) and water (5 mL) was added and the aqueous layer
further extracted with CH2Cl2 (3 × 30 mL). The organic layers were combined, dried (MgSO4) and the
solvent removed in vacuo. The crude product was purified by column chromatography (2:1 hexanes,
ethyl acetate) to give the title compound 9b (1.4 g, 60%) as a pale yellow oil. Rf = 0.39 (1:2 hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 2.43 (4H, br t, J = 4.7 Hz, NCH2CH2O), 2.96 (2H, d, J = 6.5 Hz,
1-H), 3.28 (2H, d, J = 7.0 Hz, 4-H), 3.71 (4H, t, J = 4.7 Hz, NCH2CH2O), 5.49–5.56 (1H, m, 2-H), 5.69–5.76
(1H, m, 3-H), 5.91 (2H, d, J = 2.0 Hz, OCH2O), 6.61 (1H, dd, J = 7.5, 2.0 Hz, 6′-H), 6.65 (1H, d, J = 2.0 Hz,
2′-H), 6.72 (1H, d, J = 7.5 Hz, 5′-H). δC (100 MHz; CDCl3) 38.7 (C-4), 53.7 (NCH2CH2O), 61.2 (C-1),
67.1 (NCH2CH2O), 100.9 (OCH2O), 108.3 (C-5′), 109.1 (C-2′), 121.4 (C-6′), 127.4 (C-2), 133.7 (C-3), 134.1
(C-1′), 146.0 (C-4′), 147.8 (C-3′). IR: νMAX (film)/cm−1; 2855, 1739, 1488, 1242, 1115, 1036, 926, 864, 736.
HRMS (ESI+) Found [M + H]+ 262.1428; C15H20NO3 requires 262.1438.
(E)-Ethyl-3-(3′,4′-methylenedioxyphenyl)prop-2-enoate (23). To a stirred solution of piperonal
20 (5.0 g, 33 mmol) in CH2Cl2 (100 mL), under an atmosphere of nitrogen, was added
(carbethoxymethylene)triphenylphosphorane (12.8 g, 37.0 mmol) and the resulting mixture stirred for
20 h. Solvent was then removed in vacuo and the crude product purified by column chromatography
(3:1, hexanes, ethyl acetate) to give the title compound 23 (6.97 g, 95%) as a white solid. Rf = 0.68
(2:1 hexanes, ethyl acetate). Melting point: 62–64 ◦C. δH (400 MHz; CDCl3) 1.32 (3H, t, J = 7.2 Hz,
1-OCH2CH3), 4.25 (2H, q, J = 7.2 Hz, 1-OCH2CH3), 6.00 (2H, s, -OCH2O-), 6.25 (1H, d, J = 15.9 Hz, 2-H),
6.80 (1H, d, J = 8.0 Hz, 5′-H), 7.00 (1H, dd, J = 1.4, 8.0 Hz, 6′-H), 7.02 (1H, d, J = 1.4 Hz, 6′-H), 7.58 (1H,
d, J = 15.9 Hz, 3-H). δC (100 MHz; CDCl3) 14.5 (1-OCH2CH3), 60.5 (1-OCH2CH3), 101.7 (-OCH2O-),
106.6 (C-5′), 108.7 (C-2′), 116.4 (C-2), 124.5 (C-6′), 129.1 (C-1′), 144.4 (C-3), 148.5 (C-4′), 149.7 (C-3′),
167.3 (C-1). Values are in agreement with literature data [44].
(E)-Ethyl-3-(3′,4′,5′-trimethoxyphenyl)prop-2-enoate (24). To a stirred solution of 3,4,5-
trimethoxybenzaldehyde 21 (3.0 g, 15.3 mmol) in CH2Cl2 (100 mL), under an atmosphere of
nitrogen, was added (carbethoxymethylene)triphenylphosphorane (5.9 g, 16.8 mmol) and the resulting
mixture stirred for 3 h. Solvent was then removed in vacuo and the crude product purified by column
chromatography (3:1, hexanes, ethyl acetate) to give the title compound 24 (4.0 g, 94%) as a white
solid. Rf = 0.52 (2:1 hexanes, ethyl acetate). Melting point: 64–66 ◦C. δH (400 MHz; CDCl3) 1.34
(3H, t, J = 7.2 Hz, 1-OCH2CH3), 3.87 (3H, s, 4′-OCH3), 3.88 (6H, s, 3′-OCH3), 4.26 (2H, q, J = 7.2 Hz,
1-OCH2CH3), 6.34 (1H, d, J = 15.9 Hz, 2-H), 6.75 (2H, s, 2′-H), 7.60 (1H, d, J = 15.9 Hz, 3-H). δC
(100 MHz; CDCl3) 14.5 (1-OCH2CH3), 56.3 (3′-OCH3), 60.6 (1-OCH2CH3), 61.1 (4′-OCH3), 105.3 (C-2′),
117.7 (C-2), 130.1 (C-1′), 140.2 (C-4′), 144.7 (C-3), 153.6 (C-3′), 167.1 (C-1). Values are in agreement with
literature data [45].
3-(3′,4′,5′-Trimethoxyphenyl)propionic acid (31). To a stirred solution of 24 (5.4 g, 19.4 mmol) in ethyl
acetate (30 mL) was added 10% palladium on activated carbon (0.54 g, 10% w/w). The solution was
flushed with an atmosphere of hydrogen and stirred for 2 h. The reaction mixture was then filtered
through a plug of celite and washed with ethyl acetate, solvent was then removed in vacuo to give
saturated ester 27 (5.23 g, 96%) which was then used without further purification.
To a stirred solution of ester 27 (5.1 g, 17.9 mmol) in methanol (30 mL) was added aqueous NaOH
(72 mL, 1 M, 4 eq.) and stirred for 20 min. The mixture was then extracted with CH2Cl2 (10 mL) and
the aqueous layer acidified with aqueous 2 M HCl. The aqueous phase was then extracted with ethyl
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acetate (3 × 50 mL), dried (MgSO4) and solvent removed in vacuo to give the title compound 31 (4.6 g,
quant.) as a white solid. Rf = 0.15 (2:1 hexanes, ethyl acetate). Melting point: 104–105 ◦C. δH (400 MHz;
CDCl3) 2.68 (2H, t, J = 7.8 Hz, 2-H), 2.90 (2H, t, J = 7.8 Hz, 3-H), 3.82 (3H, s, 4′-OCH3), 3.84 (6H, s,
3′-OCH3), 6.43 (2H, s, 2′-H). δC (100 MHz; CDCl3) 31.1 (C-2), 35.8 (C-3), 56.2 (3′-OCH3), 61.0 (4′-OCH3),
105.4 (C-2′), 136.0 (C-1′), 136.7 (C-4′), 153.4 (C-3′), 178.8 (C-1). Values are in agreement with literature
data [46].
3-(3′,4′-Methylenedioxyphenyl)propionic acid (30). To a stirred solution of 23 (6.92 g, 31.4 mmol) in ethyl
acetate (30 mL) was added 10% palladium on activated carbon (0.69 g, 10% w/w). The solution was
flushed with an atmosphere of hydrogen and stirred for 1 h. The reaction mixture was then filtered
through a plug of celite and washed with ethyl acetate, solvent was then removed in vacuo to give
saturated ester 26 (6.9 g, 99%) which was then used without further purification.
To a stirred solution of ester 26 (6.74 g, 30.0 mmol) in methanol (30 mL) was added aqueous NaOH
(121 mL, 1 M, 4 eq.) and stirred for 2.5 h. The mixture was then extracted with ethyl acetate (10 mL) and
the aqueous layer acidified with aqueous 2 M HCl. The aqueous phase was then extracted with ethyl
acetate (3 × 50 mL), dried (MgSO4) and solvent removed in vacuo to give the title compound 30 (5.5 g,
94%) as a white solid. Rf = 0.44 (2:1 hexanes, ethyl acetate). Melting point: 80–82◦C. δH (400 MHz;
CDCl3) 2.64 (2H, t, J = 7.7 Hz, 2-H), 2.88 (2H, t, J = 7.7 Hz, 3-H), 5.93 (2H, s, -OCH2O-), 6.66 (1H, dd, J =
7.9, 1.4 Hz, 6′-H), 6.70 (1H, d, J = 1.4 Hz, 2′-H), 6.74 (1H, d, J = 7.9 Hz, 5′-H). δC (100 MHz; CDCl3) 30.5
(C-2), 36.1 (C-3), 101.0 (-OCH2O-), 108.4 (C-2′), 108.9 (C-5′), 121.2 (C-6′), 134.1 (C-1′), 146.2 (C-3′), 147.8
(C-4′), 179.1 (C-1). Values are in agreement with literature data [47].
3-(3′-Methoxy-4′-benzyloxyphenyl)propionic acid (32). To a stirred solution of vanillin 22
(3.0 g, 19.7 mmol) in CH2Cl2 (100 mL), under an atmosphere of nitrogen, was added
(carbethoxymethylene)triphenylphosphorane (7.56 g, 21.7 mmol) and the resulting mixture stirred for
18 h. Solvent was then removed in vacuo and the crude product purified by column chromatography
(2:1, hexanes, ethyl acetate) to give a 2:1 mixture of E and Z isomers of unsaturated ester 25 (4.13 g,
94%) as a yellow oil which was used immediately.
To a stirred solution of unsaturated ester 25 (4.13 g, 18.6 mmol) in ethyl acetate (30 mL) was added
10% palladium on activated carbon (0.4 g, 10% w/w). The solution was flushed with an atmosphere
of hydrogen and stirred for 2 h. The reaction mixture was then filtered through a plug of celite and
washed with ethyl acetate, solvent was then removed in vacuo to give saturated ester 28 (3.9 g, 94%)
as a yellow oil which was then used without further purification. To a stirred solution of phenol 28
(3.75 g, 16.7 mmol) in acetonitrile (40 mL), under an atmosphere of nitrogen, was added K2CO3 (6.9 g,
50.0 mmol) and stirred for 10 min. Benzyl bromide (6.0 mL, 50.0 mmol) was then added and the
resulting mixture allowed to stir for 65 h. The reaction mixture was then quenched with addition of
water (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The organic phases were combined, washed
with water (2 × 10 mL) and dried (MgSO4). Solvent was then removed in vacuo and the crude product
purified by column chromatography (9:1 hexanes, ethyl acetate) to give benzyl ether 29 (4.38 g, 83%)
as a colourless oil which was used immediately. To a stirred solution of ester 29 (4.3 g, 13.7 mmol) in
methanol (30 mL) was added aqueous NaOH (55 mL, 1 M, 4 eq.) and stirred for 2.5 h. The mixture
was then acidified with aqueous 2 M HCl, extracted with ethyl acetate (3 × 50 mL), dried (MgSO4)
and solvent removed in vacuo to give the title compound 32 (3.85 g, 98%) as a white solid. Rf = 0.30
(2:1 hexanes, ethyl acetate). Melting point: 99–100◦C. δH (400 MHz; CDCl3) 2.66 (2H, t, J = 7.7 Hz, 2-H),
2.90 (2H, t, J = 7.7 Hz, 3-H), 3.88 (3H, s, 3′-OCH3), 5.13 (2H, s, 7′-H), 6.68 (1H, dd, J = 8.2, 2.0 Hz, 6′-H),
6.76 (1H, d, J = 2.0 Hz, 2′-H), 6.81 (1H, d, J = 8.2 Hz, 5′-H), 7.27–7.32 (1H, m, 11′-H), 7.34–7.39 (2H, m,
10′-H), 7.41–7.45 (2H, m, 9′-H). δC (100 MHz; CDCl3) 30.4 (C-2), 35.9 (C-3), 56.1 (3′-OCH3), 71.3 (C-7′),
112.4 (C-2′), 114.5 (C-5′), 120.3 (C-6′), 127.4 (C-9′), 127.9 (C-11′), 128.7 (C-10′), 133.5 (C-1′), 137.4 (C-8′),
146.9 (C-4′), 149.8 (C-3′), 178.8 (C-1). Values are in agreement with literature data [48].
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3-(3′,4′-Methylenedioxyphenyl)propanoyl chloride (34b). To a stirred solution of carboxylic acid 30 (0.22 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 4 h. The solvent was removed in vacuo to give the
title compound 34b (0.24 g, quant.) as a green oil, which was placed under nitrogen and used without
further purification.
3-(3′,4′-Dimethoxyphenyl)propanoyl chloride (34a). To a stirred solution of carboxylic acid 33 (0.24 g,
1.2 mmol) in CH2Cl2 (5 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 2.5 h. The solvent was removed in vacuo to give the
title compound 34a (0.26 g, quant.) as a yellow oil, which was placed under nitrogen and used without
further purification.
3-(3′,4′,5′-Trimethoxyphenyl)propanoyl chloride (34c). To a stirred solution of carboxylic acid 31 (0.25 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 1.5 h. The solvent removed in vacuo to give the title
compound 34c (0.27 g, quant.) as a green crystalline solid, which was placed under nitrogen and used
without further purification.
3-(3′,4′-Methylenedioxyphenyl)propanoyl chloride (34d). To a stirred solution of carboxylic acid 32 (0.33 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 4 h. The solvent was removed in vacuo to give the title
compound 34d (0.35 g, quant.) as a yellow oil, which was placed under nitrogen and used without
further purification.
(2R*,3S*)-2-(3′,4′-Methylenedioxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35ab).
Using general procedure A: Morpholine 9a (0.57 g, 2.06 mmol), acid chloride 34b (0.52 g, 2.47 mmol)
and reaction time of 24 h. The crude product was purified by column chromatography (2:1 hexanes,
ethyl acetate) to give the title compound 35ab (0.39 g, 42%) as a pale-yellow amorphous solid. Rf =
0.58 (1:3, hexanes, ethyl acetate). Melting point: 114–116 ◦C. δH (400 MHz; CDCl3) 2.57 (1H, dd, J =
13.6, 9.0 Hz, 7′′-HA), 2.66–2.73 (1H, m, 3-H), 2.77–2.85 (2H, m, 7′-HA, OCHACH2N), 2.85–2.94 (4H,
m, 2-H, 7′-HB, 7′′-HB, OCH2CHAN), 3.06 (1H, ddd, J = 13.3, 7.9, 3.3 Hz, OCH2CHBN), 3.27–3.41 (3H,
m, OCHCCHCN, OCHBCH2N), 3.53–3.60 (1H, m, OHDCH2N), 3.67–3.75 (1H, m, OCH2CHDN), 3.85
(3H, s, 4′′-OCH3), 3.86 (3H, s, 3′′-OCH3), 4.88 (1H, dd, J = 16.9, 1.8 Hz, 5-HA), 4.98 (1H, dd, J = 10.3,
1.8 Hz, 5-HB), 5.85 (1H, ddd, J = 16.9, 10.3, 9.5 Hz, 4-H), 5.90 (1H, d, J = 1.3 Hz, OCHAO), 5.91 (1H, d,
J = 1.3 Hz, OCHBO), 6.60 (1H, dd, J = 7.8, 1.6 Hz, 6′-H), 6.64 (1H, d, J = 1.6 Hz, 2′-H), 6.65–6.68 (2H,
m, 2′′, 6′′-H), 6.70 (1H, d, J = 7.8 Hz, 5′-H), 6.77 (1H, d, J = 8.7 Hz, 5′′-H). δC (100 MHz; CDCl3) 37.4
(C-7′), 38.3 (C-7′′), 42.0 (OCH2CHCDN), 46.4 (OCH2CHABN), 46.6 (C-2), 48.5 (C-3), 56.0 (3′, 4′-OCH3),
66.4 (OCHABCH2N), 67.0 (OCHCDCH2N), 101.0 (OCH2O), 108.4 (C-5′), 109.6 (C-2′), 111.1 (C-5′′), 112.4
(C-2′′), 116.8 (C-5), 121.3 (C-6′′), 122.0 (C-6′), 132.3 (C-1′′), 133.6 (C-1′), 139.3 (C-4), 146.2 (C-4′), 147.5
(C-4′′), 147.7 (C-3′), 148.9 (C-3′′), 172.6 (C-1). IR: νMAX (film)/cm-1; 2963, 1631, 1515, 1488, 1442, 1236,
1031, 925, 807, 730. HRMS (ESI+) Found [M + H]+ 454.2241; C26H32NO6 requires 454.2224.
(2R*,3S*)-2-(3′,4′,5′-Trimethoxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35ac).
Using general procedure A: Morpholine 9a (0.47 g, 1.7 mmol), acid chloride 34c (0.53 g, 2.0 mmol) and
a reaction time of 19 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl
acetate) to give the title compound 35ac (0.50 g, 58%) as a yellow oil. Rf = 0.38 (1:3 hexanes, ethyl
acetate). δH (400 MHz; CDCl3) 2.59 (1H, dd, J = 13.6, 9.2 Hz, 7′′-HA), 2.67–2.74 (1H, m, 3-H), 2.78
(1H, ddd, J = 11.4, 7.8, 3.0 Hz, NCH2CHAO), 2.82–2.96 (5H, m, 2-H, 7′-H, 7′′-HB, NCHACH2O), 3.06
(1H, ddd, J = 13.2, 7.8, 3.0 Hz, NCHBCH2O), 3.25–3.40 (3H, m, NCHBCH2O, NCHCCHCO), 3.54–3.61
(1H, m, NCHDCH2O), 3.67–3.73 (1H, m, NCH2CHDO), 3.80 (3H, s, 4′-OCH3), 3.82 (6H, s, 3′-OCH3),
3.85 (3H, s, 4′′-OCH3), 3.86 (3H, s, 3′′-OCH3), 4.90 (1H, dd, J = 17.0, 1.8 Hz, 5-HA), 5.00 (1H, dd, J =
10.2, 1.8 Hz, 5-HB), 5.87 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 6.37 (2H, s, 2′-H), 6.66–6.70 (2H, m, 2′′,
6′′-H), 6.78 (1H, d, J = 8.7 Hz, 5′′-H). δC (100 MHz; CDCl3) 38.1 (C-7′), 38.3 (C-7′′), 42.0 (NCHCDCH2O),
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46.4 (NCHABCH2O), 46.5 (C-2), 48.7 (C-3), 56.0 (3′′, 4′′-OCH3), 56.3 (3′-OCH3), 61.0 (4′-OCH3), 66.4
(NCH2CHABO), 66.9 (NCH2CHCDO), 106.2 (C-2′), 111.1 (C-5′′), 112.5 (C-2′′), 116.8 (C-5), 121.2 (C-6′′),
132.3 (C-1′′), 135.6 (C-1′), 136.8 (C-4′), 139.2 (C-4), 147.5 (C-4′′), 148.8 (C-3′′), 153.3 (C-3′), 172.6 (C-1). IR:
νMAX (film)/cm-1; 2940, 1632, 1589, 1459, 1236, 1123, 1028, 913, 735. HRMS (ESI+) Found [M + Na]+
522.2474; C28H37NNaO7 requires 522.2462.
(2R*,3S*)-2-(3′,4′-Dimethoxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35aa). Using
general procedure A: Morpholine 9a (0.53 g, 1.91 mmol), acid chloride 34a (0.52 g, 2.29 mmol) and
a reaction time of 24 h. The crude product was purified by flash chromatography (1:3 hexanes, ethyl
acetate) to give the title compound 35aa (0.63 g, 77% yield) as a pale-yellow amorphous solid. Rf = 0.42
(19:1 CH2Cl2, methanol). Melting point: 98–101 ◦C. δH (400 MHz; CDCl3) 2.55–2.63 (1H, m, 7′′-HA),
2.85–2.93 (1H, m, 7′′-HB), 2.67–2.85 (3H, m, 3-H, OCH2CHABN), 3.29-3.37 (4H, m, OCH2CHCDN,
OCHABCH2N), 2.85–3.06 (3H, m, 2-H, 7′-H), 3.50–3.67 (2H, m, OCHCDCH2N), 3.83, 3.84, 3.85, 3.86
(12H, s, 3′, 4′, 3′′, 4′′-OCH3), 4.89 (1H, dd, J = 17.1, 1.7 Hz, 5-H), 4.99 (1H, dd, J = 10.3, 1.9 Hz, 5-H),
5.82–5.91 (1H, m, 4-H), 6.67–6.69 (4H, m, 2′, 6′, 2′′, 6′′-H), 6.75–6.78 (2H, m, 5′, 5′′-H). δC (100 MHz;
CDCl3) 37.2 (C-2), 38.2 (C-7′′), 41.9, 46.5 (OCH2CH2N), 46.2 (C-7′), 48.5 (C-3), 55.8, 55.9 (3′, 4′, 3′′,
4′′-OCH3), 66.3, 66.8 (OCH2CH2N), 111.0, 111.3 (C-5′, 5′′), 112.4, 112.6 (C-2′, 2′′), 116.6 (C-5), 120.9,
121.2 (C-6′, 6′′), 132.2, 132.3 (C-1′, 1′′), 139.2 (C-4), 147.3, 147.6 (4′, 4′′-OCH3), 148.7, 148.8 (3′, 3′′-OCH3),
172.6 (C-1). IR: νMAX (film)/cm−1; 2935, 1628, 1591, 1462, 1260, 1155, 1027, 912, 857, 765. HRMS (ESI+)
Found [M + H]+ 470.2537; C27H36NO6 requires 470.2537
(2R*,3S*)-2-(3′-Methoxy-4′-benzyloxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholino-pent-4-en-1-one
(35ad). Using general procedure A: Morpholine 9a (0.47 g, 1.7 mmol), acid chloride 34d (0.62 g, 2.0
mmol) and a reaction time of 22 h. The crude product was purified by column chromatography (2:1
hexanes, ethyl acetate) to give the title compound 35ad (0.59 g, 64%) as a yellow oil.
Rf = 0.58 (1:3, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.57 (1H, dd, J = 13.5, 9.0 Hz, 7′′-HA),
2.62–2.68 (1H, m, 3-H), 2.68–2.74 (1H, m, OCHACH2N), 2.75–2.82 (1H, m, OCH2CHAN), 2.83–2.92 (4H,
m, 2-H, 7′-H, 7′′-HB), 2.99 (1H, ddd, J = 13.3, 7.6, 3.2 Hz, OCH2CHBN), 3.20–3.32 (3H, m, OCHBCH2N,
OCHCCHCN), 3.50–3.55 (1H, m, OCHDCH2N), 3.61–3.67 (1H, m, OCH2CHDN), 3.84 (3H, s, 3′-OCH3),
3.85 (3H, s, 4′′-OCH3), 3.85 (3H, s, 3′′-OCH3), 4.88 (1H, dd, J = 17.1, 1.9 Hz, 5-HA), 4.97 (1H, dd, J = 10.3,
1.9 Hz, 5-HB), 5.13 (1H, s, 7′′′-H), 5.85 (1H, ddd, J = 17.1, 10.3, 9.0 Hz, 4-H), 6.59 (1H, dd, J = 8.1, 1.9 Hz,
6′-H), 6.65–6.68 (2H, m, 2′′-H, 6′′-H), 6.69 (1H, d, J = 1.9 Hz, 2′-H), 6.74 (1H, d, J = 8.1 Hz, 5′-H), 6.77
(1H, d, J = 8.5 Hz, 5′′-H), 7.25–7.30 (1H, m, 4′′′-H), 7.32–7.37 (2H, m, 3′′′-H), 7.38–7.42 (2H, m, 2′′′-H).
δC (100 MHz; CDCl3) 37.4 (C-7′), 38.3 (C-7′′), 41.9 (OCH2CHCDN), 46.3 (OCH2CHABN), 46.5 (C-2), 48.6
(C-3), 56.0, 56.2 (3′, 3′′, 4′′-OCH3), 66.4 (OCHABCH2N), 66.9 (OCHCDCH2N), 71.2 (C-7′′′), 111.1 (C-5′′),
112.4 (C-2′′), 113.3 (C-2′), 114.6 (C-5′), 116.7 (C-5), 120.9 (C-6′), 121.3 (C-6′′), 127.3 (C-2′′′), 127.9 (C-4′′′),
128.7 (C-3′′′), 132.4 (C-1′′), 133.1 (C-1′), 137.3 (C-1′′′), 139.3 (C-4), 146.7 (C-4′), 147.5 (C-4′′), 148.8 (C-3′′),
149.7 (C-3′), 172.7 (C-1). IR: νMAX (film)/cm−1; 2936, 1736, 1633, 1513, 1454, 1261, 1140, 1028, 915, 733.
HRMS (ESI+) Found [M + Na]+ 568.2671; C33H39NNaO6 requires 568.2670.
(2R*,3S*)-2-(3′,4′-Dimethoxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one (35ba).
Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34a (0.26 g, 1.2 mmol)
and a reaction time of 21 h. The crude product was purified by column chromatography (1:1 hexanes,
ethyl acetate) to give the title compound 35ba (0.36 g, 83%) as a yellow oil.
Rf = 0.50 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.56 (1H, dd, J = 13.4, 9.0 Hz, 7′′-HA),
2.62–2.70 (1H, m, 3-H), 2.75–2.94 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.05 (1H, ddd, J = 13.6, 7.9,
3.1 Hz, NCHBCH2O), 3.28–3.41 (3H, m, NCH2CHBO, NCHCCHCO), 3.51–3.57 (1H, m, NCH2CHDO),
3.58–3.64 (1H, m, NCHDCH2O), 3.83 (3H, s, 3′-H), 3.84 (3H, s, 4′-H), 4.89 (1H, dd, J = 17.2, 1.9 Hz,
5-HA), 4.99 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.86 (1H, ddd, J = 17.2, 10.2, 9.1 Hz, 4-H), 5.92 (1H, d,
J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO), 6.58 (1H, dd, J = 7.9, 1.6 Hz, 6′′-H), 6.64 (1H, d,
J = 1.6 Hz, 2′′-H), 6.66–6.70 (2H, m, 2′, 6′-H), 6.71 (1H, d, J = 7.9 Hz, 5′′-H), 6.76 (1H, d, J = 8.1 Hz, 5′-H).
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δC (100 MHz; CDCl3) 37.3 (C-7′), 38.5 (C-7′′), 42.0 (NCHABCH2O), 46.3 (NCHCDCH2O), 46.5 (C-2),
48.8 (C-3), 56.1 (3′, 4′-OCH3), 66.4 (NCH2CHABO), 66.9 (NCH2CHCDO), 101.0 (OCH2O), 108.1 (C-5′′),
109.6 (C-2′′), 111.4 (C-5′), 112.7 (C-2′), 116.8 (C-5), 121.0 (C-6′), 122.1 (C-6′′), 132.4 (C-1′), 133.7 (C-1′′),
139.2 (C-4), 145.9 (C-4′′), 147.6 (C-4′), 147.8 (C-3′′), 149.0 (C-3′), 172.7 (C-1). IR: νMAX (film)/cm−1; 2908,
1740, 1630, 1515, 1441, 1237, 1029, 923, 730. HRMS (ESI+) Found [M + Na]+ 476.2042; C26H31NNaO6
requires 476.2044.
(2R*,3S*)-2-(3′,4′-Methylenedioxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one
(35bb). Using general procedure A: Morpholine 9b (0.5 g, 1.91 mmol), acid chloride 34b (0.49 g,
2.30 mmol) and a reaction time of 30 min. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 35bb (0.798 g, 95%) as a pale-yellow solid. Rf =
0.68 (1:3 hexanes, ethyl acetate). Melting point: 131–133 ◦C. δH (400 MHz; CDCl3) 2.54 (1H, dd, J =
13.5, 8.9 Hz, 7′′-HA), 2.61–2.69 (1H, m, 3-H), 2.78–2.93 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.06
(1H, ddd, J = 13.2, 7.8, 3.1 Hz, NCHBCH2O), 3.29–3.41 (3H, m, NCH2CHBO, NCHCCHCO), 3.53–3.61
(1H, m, NCH2CHDO), 3.66–3.74 (1H, m, NCHDCH2O), 4.89 (1H, dd, J = 17.0, 1.9 Hz, 5-HA), 4.99
(1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.85 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 5.90 (1H, d, J = 1.4 Hz,
3′-OCHAO), 5.91 (1H, d, J = 1.4 Hz, 3′-OCHBO), 5.92 (1H, d, J = 1.5 Hz, 3′′-OCHAO), 5.93 (1H, d,
J = 1.5 Hz, 3′′-OCHBO), 6.55–6.61 (2H, m, 6′, 6′′-H), 6.62–6.64 (2H, m, 2′, 2′′-H), 6.70, 6.71 (2 × 1H,
2 × d, J = 8.0 Hz, 5′, 5′′-H). δC (100 MHz; CDCl3) 37.4 (C-7′), 38.5 (C-7′′), 42.0 (NCHCDCH2O), 46.4
(NCHABCH2O), 46.5 (C-2), 48.8 (C-3), 66.4 (NCH2CHABO), 67.0 (NCH2CHCDO), 101.0 (2 × OCH2O),
108.2, 108.4 (C-5′, 5′′), 109.6 (C-2′, 2′′), 116.8 (C-5), 122.1 (C-6′, 6′′), 133.6 (C-1′, 1′′), 139.2 (C-4), 145.9,
146.2 (C-4′, 4′′), 147.6, 147.7 (C-3′, 3′′), 172.6 (C-1). IR: νMAX (film)/cm−1; 2897, 1630, 1487, 1440, 1244,
1036, 925, 808, 730. HRMS (ESI+) Found [M + Na]+ 460.1722; C25H27NNaO6 requires 460.1731.
(2R*,3S*)-2-(3′,4′,5′-Trimethoxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one (35bc).
Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34c (0.27 g, 1.2 mmol) and
a reaction time of 18 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl
acetate) to give the title compound 35bc (0.40 g, 86%) as a pale-yellow solid. Rf = 0.55 (1:3 hexanes,
ethyl acetate). Melting point: 104–106 ◦C. δH (400 MHz; CDCl3) 2.56 (1H, dd, J = 13.4, 9.0 Hz, 7′′-HA),
2.62–2.70 (1H, m, 3-H), 2.75–2.95 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.06 (1H, ddd, J = 13.2, 7.7,
3.0 Hz, NCHBCH2O), 3.25–3.40 (3H, m, NCH2CHBO, NCHCCHCO), 3.54–3.60 (1H, m, NCH2CHDO),
3.65–6.71 (1H, m, NCHDCH2O), 3.80 (3H, s, 4′-OCH3), 3.82 (6H, s, 3′-OCH3), 4.90 (1H, dd, J = 17.2, 1.9
Hz, 5-HA), 5.00 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.85 (1H, ddd, J = 17.2, 10.2, 9.0 Hz, 4-H), 5.92 (1H, d,
J = 1.4 Hz, OCHAO), 5.93 (1H, d, J = 1.4 Hz, OCHBO), 6.36 (2H, s, 2′-H), 6.59 (1H, dd, J = 7.9, 1.6 Hz,
6′′-H), 6.65 (1H, d, J = 1.6 Hz, 2′′-H), 6.72 (1H, d, J = 7.9 Hz, 5′′-H). δC (100 MHz; CDCl3) 38.1 (C-7′),
38.5 (C-7′′), 42.0 (NCHCDCH2O), 46.4 (C-2, NCHABCH2O), 48.9 (C-3), 56.4 (3′-OCH3), 61.1 (4′-OCH3),
66.4 (NCH2CHABO), 67.0 (NCH2CHCDO), 101.0 (OCH2O), 106.2 (C-2′), 108.2 (C-5′′), 109.6 (C-2′′), 116.9
9 (C-5), 122.1 (C-6′′), 133.6 (C-1′′), 135.6 (C-1′), 136.9 (C-4′), 139.1 (C-4), 145.9 (C-4′′), 147.7 (C-3′′), 153.3
(C-3′), 172.6 (C-1). IR: νMAX (film)/cm−1; 2922, 1632, 1589, 1490, 1240, 1120, 1036, 925, 730. HRMS
(ESI+) Found [M + Na]+ 506.2145; C27H33NNaO7 requires 506.2149.
(2R*,3S*)-2-(3′-Methoxy-4′-benzyloxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one
(35bd). Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34d (0.35 g,
1.2 mmol) and a reaction time of 18 h. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 35bd (0.45 g, 88%) as a yellow oil.
Rf = 0.67 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.54 (1H, dd, J = 13.5, 8.9 Hz, 7′′-HA),
2.61–2.70 (2H, m, 3-H, NCH2CHAO), 2.73–2.91 (5H, m, 2-H, 7′-H, 7′′-HB, NCHACH2O), 2.99 (1H,
ddd, J = 13.2, 7.7, 3.0 Hz, NCHBCH2O), 3.20–3.35 (3H, m, NCH2CHBO, NCHCCHCO), 3.53 (1H, ddd,
J = 11.0, 5.5, 2.5 Hz, NCH2CHDO), 3.62 (1H, ddd, J = 13.0, 5.5, 2.5 Hz, NCHDCH2O), 3.84 (3H, s,
3′-OCH3), 4.88 (1H, dd, J = 17.0, 1.9 Hz, 5-HA), 4.98 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.13 (2H, s, 7′′′-H),
5.84 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz,
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OCHBO), 6.57 (1H, dd, J = 8.0, 1.9 Hz, 6′′-H), 6.59 (1H, dd, J = 8.2, 1.8 Hz, 6′-H), 6.64 (1H, d, J = 1.8 Hz,
2′′-H), 6.69 (1H, d, J = 1.9 Hz, 2′′-H), 6.71 (1H, d, J = 8.0 Hz, 5′′-H), 6.75 (1H, d, J = 8.2 Hz, 5′-H),
7.25–7.30 (1H, m, 4′′′-H), 7.32–7.37 (2H, m, 3′′′-H), 7.38–7.43 (2H, m, 2′′′-H). δC (100 MHz; CDCl3) 37.4
(C-7′), 38.5 (C-7′′), 41.9 (NCHCDCH2O), 46.3 (NCHABCH2O), 46.4 (C-2), 48.8 (C-3), 56.2 (3′-OCH3), 66.3
(NCH2CHABO), 66.9 (NCH2CHCDO), 71.2 (C-7′′′), 100.9 (OCH2O), 108.1 (C-5′′), 109.6 (C-2′′), 113.2
(C-2′), 114.5 (C-5′), 116.7 (C-5), 121.0 (C-6′), 122.1 (C-6′′), 127.3 (C-2′′′), 127.9 (C-4′′′), 128.6 (C-3′′′),
133.1 (C-1′) 133.6 (C-1′′), 137.3 (C-1′′′), 139.2 (C-4), 145.9 (C-4′′), 146.7 (C-4′), 147.6 (C-3′′), 149.7 (C-3′),
172.6 (C-1). IR: νMAX (film)/cm−1; 2920, 1630, 1489, 1231, 1114, 1034, 913, 729. HRMS (ESI+) Found
[M + Na]+ 552.2354; C32H35NNaO6 requires 552.2357.
(3R*,4R*)-3-(3′,4′-Methylenedioxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4ab). Using general procedure B: Amide 35ab (0.38 g, 0.84 mmol) in tBuOH/H2O and a reaction
time of 3 days. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 4ab (180 mg, 54%) as a white foam. Rf = 0.50 (19:1 CH2Cl2, methanol). δH
(400 MHz; CDCl3) 1.79 (1H, t, J = 6.4 Hz, 6-OH), 2.36–2.44 (1H, m, 4-H), 2.51 (1H, dd, J = 13.7, 7.9 Hz,
7′′-HA), 2.58 (1H, dd, J = 13.7, 6.6 Hz, 7′′-HB), 2.68 (1H, ddd, J = 9.3, 7.0, 5.5 Hz, 3-H), 2.85 (1H, dd, J =
14.0, 7.0 Hz, 7′-HA), 2.92 (1H, dd, J = 14.0, 5.5 Hz, 7′-HB), 3.15 (1H, ddd, J = 12.5, 6.4, 5.1 Hz, 6-HA), 3.54
(1H, ddd, J = 12.5, 6.4, 2.5 Hz, 6-HB), 3.83 (3H, s, 3′′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J =
8.0, 5.1, 2.5 Hz, 5-H), 5.92 (1H, d, J = 1.5 Hz, OCHAHBO), 5.93 (1H, d, J = 1.5 Hz, OCHAHBO), 6.47 (1H,
d, J = 2.0 Hz, 2′′-H), 6.57–6.60 (2H, m, 6′ and 6′′-H), 6.61 (1H, d, J = 1.5 Hz, 2′-H), 6.71 (1H, d, J = 7.8 Hz,
5′-H), 6.77 (1H, d, J = 8.1 Hz, 5′′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.7 (C-7′′), 41.6 (C-4), 47.6 (C-3),
56.0 (3′′-OCH3, 4′′-OCH3), 63.2 (C-6), 84.1 (C-5), 101.2 (OCH2O), 108.3 (C-5′), 109.7 (C-2′), 111.4 (C-5′′),
112.0 (C-2′′), 121.0 (C-6′′), 122.5 (C-6′), 130.3 (C-1′′), 131.6 (C-1′), 146.6 (C-4′), 148.0 (C-4′′), 148.1 (C-3′),
149.3 (C-3′′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3496 (broad), 2936, 2254, 1760, 1515, 1489, 1442, 1239,
1025, 909, 809, 766. HRMS (ESI+) Found [M + Na]+ 423.1427; C22H24NaO7 requires 423.1414.
(3R*,4R*)-3,4-bis(3′,4′-Dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (4aa). Using general
procedure B: Amide 35aa (0.29 g, 0.61 mmol), in tBuOH/H2O and a reaction time of 6 days. The crude
product was purified by flash chromatography (1:1 hexanes, ethyl acetate) to give the title compound
4aa (0.18 g, 70%) as a colourless oil. Rf = 0.32 (19:1 CH2Cl2, methanol). δH (400 MHz; CDCl3) 2.39–2.44
(1H, m, 4-H), 2.53 (1H, dd, J = 13.7, 7.3 Hz, 7′′-HA), 2.58 (1H, dd, J = 13.7, 6.5 Hz, 7′′-HB), 2.64 (1H, br s,
6-OH), 2.71 (1H, ddd, J = 9.3, 6.7, 5.7 Hz, 3-H), 2.88 (1H, dd, J = 14.0, 6.7 Hz, 7′-HA), 2.94 (1H, dd, J =
14.0, 5.5 Hz, 7′-HB), 3.16 (1H, dd, J = 12.6, 4.9 Hz, 6-HA), 3.53 (1H, dd, J = 12.6, 2.4 Hz, 6-HB), 3.81, 3.83,
3.84 (12H, s, 3′, 4′, 3′′, 4′′-OCH3), 4.15 (1H, ddd, J = 8.0, 4.9, 2.4 Hz, 5-H), 6.49 (1H, d, J = 1.9 Hz, 2′′-H),
6.57 (1H, dd, J = 8.1, 1.9 Hz, 6′′-H), 6.66–6.68 (2H, m, 2′, 6′-H), 6.73–6.80 (2H, m, 5′, 5′′-H). δC (100 MHz;
CDCl3) 35.0 (C-7′), 38.5 (C-7′′), 41.6 (C-4), 47.5 (C-3), 55.8 (3′, 4′, 3′′, 4′′-OCH3), 62.9 (C-6), 84.0 (C-5),
111.2, 111.4 (C-5′, 5′′), 112.1 (C-2′′), 112.6 (C-2′), 120.9 (C-6′′), 121.4 (C-6′), 130.4 (C-1′, 1′′), 147.9 (C-4′,
4′′), 149.0 (C-3′, 3′′), 178.0 (C-2). IR: νMAX (film)/cm−1; 3505 (br), 2938, 1761, 1591, 1514, 1465, 1259,
1156, 1025, 910, 808, 766, 647. HRMS (ESI+) Found [M + H]+ 417.1909; C23H29O7 requires 417.1908.
(3R*,4R*)-3-(3′,4′,5′-Trimethoxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one
(4ac). Using general procedure B: Amide 35ac (0.45 g, 0.90 mmol) in tBuOH/H2O/THF and a reaction
time of 3 days. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 4ac (0.17 g, 42%) as a pale-yellow solid.
Rf = 0.31 (19:1 CH2Cl2, methanol). Melting point: 141–142 ◦C. δH (400 MHz; CDCl3) 1.68 (1H, t, J =
6.5 Hz, 6-OH), 2.38–2.46 (1H, m, 4-H), 2.55 (1H, dd, J = 13.8, 8.2 Hz, 7′′-HA), 2.65 (1H, dd, J = 13.8, 5.9
Hz, 7′′-HB), 2.72 (1H, ddd, J = 9.7, 6.3, 5.7 Hz, 3-H), 2.90 (1H, dd, J = 14.0, 6.3 Hz, 7′-HA), 2.95 (1H, dd,
J = 14.0, 5.7 Hz, 7′-HB), 3.15 (1H, ddd, J = 12.4, 5.1, 5.4 Hz, 6-HA), 3.54 (1H, ddd, J = 12.4, 6.5, 2.5 Hz,
6-HB), 3.82 (6H, s, 4′, 3′′-OCH3), 3.83 (6H, s, 3′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.20 (1H, ddd, J = 8.2,
5.1, 2.5 Hz, 5-H), 6.38 (2H, s, 2′-H), 6.49 (1H, d, J = 2.0 Hz, 2′′-H), 6.58 (1H, dd, J = 8.1, 2.0 Hz, 6′′-H),
6.76 (1H, d, J = 8.1 Hz, 5′′-H). δC (100 MHz; CDCl3) 35.7 (C-7′), 38.6 (C-7′′), 41.8 (C-4), 47.7 (C-3), 56.0,
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56.1 (3′′, 4′′-OCH3), 56.3 (3′-OCH3), 61.0 (4′-OCH3), 63.2 (C-6), 83.9 (C-5), 106.5 (C-2′), 111.5 (C-5′′),
112.2 (C-2′′), 121.0 (C-6′′), 130.3 (C-1′′), 133.7 (C-1′), 137.2 (C-4′), 148.2 (C-4′′), 149.3 (C-3′′), 153.5 (C-3′),
177.7 (C-2). IR: νMAX (film)/cm−1; 3527 (br), 2938, 1761, 1590, 1514, 1237, 1126, 1026, 735. HRMS (ESI+)
Found [M + Na]+ 469.1839; C24H30NaO8 requires 469.1833.
(3R*,4R*)-3-(3′-Methoxy-4′-benzyloxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4ad). Using general procedure B: Amide 35ad (0.59 g, 1.1 mmol) in tBuOH/H2O and
a reaction time of 7 days. The crude product was purified by column chromatography (1:1 hexanes,
ethyl acetate) to give the title compound 4ad (0.30 g, 56%) as a cloudy oil. Rf = 0.27 (19:1 CH2Cl2,
methanol). δH (400 MHz; CDCl3) 1.57 (1H, t, J = 6.5 Hz, 6-OH), 2.34–2.42 (1H, m, 4-H), 2.50 (1H, dd, J =
13.5, 8.0 Hz, 7′′-HA), 2.59 (1H, dd, J = 13.5, 6.0 Hz, 7′′-HB), 2.70 (1H, ddd, J = 9.7, 6.2, 5.6 Hz, 3-H), 2.90
(1H, dd, J = 14.1, 6.2 Hz, 7′-HA), 2.94 (1H, dd, J = 14.1, 5.6 Hz, 7′-HB), 3.10 (1H, ddd, J = 12.5, 6.5, 5.2
Hz, 6-HA), 3.48 (1H, ddd, J = 12.5, 6.5, 2.7 Hz, 6-HB), 3.80 (3H, s, 3′′-OCH3), 3.86 (6H, s, 3′, 4′′-OCH3),
4.18 (1H, ddd, J = 8.3, 5.2, 2.7 Hz, 5-H), 5.12 (2H, s, 7′′′-H), 6.46 (1H, d, J = 2.0 Hz, 2′′-H), 6.56 (1H, dd,
J = 8.0, 2.0 Hz, 6′′-H), 6.61 (1H, dd, J = 8.1, 2.0 Hz, 6′-H), 6.72 (1H, d, J = 2.0 Hz, 2′-H), 6.75 (1H, d, J =
8.0 Hz, 5′′-H), 6.79 (1H, d, J = 8.1 Hz, 5′-H), 7.25–7.30 (1H, m, 4′′′-H), 7.31–7.36 (2H, m, 3′′′-H), 7.39–7.42
(2H, m, 2′′′-H). δC (100 MHz; CDCl3) 35.1 (C-7′), 38.6 (C-7′′), 41.7 (C-4), 47.6 (C-3), 56.0 (3′′, 4′′-OCH3),
56.2 (3′-OCH3), 63.3 (C-6), 71.3 (C-7′′′), 84.0 (C-5), 111.5 (C-5′′), 112.1 (C-2′′), 113.3 (C-2′), 114.3 (C-5′),
121.0 (C-6′′), 121.6 (C-6′), 127.4 (C-2′′′), 128.0 (C-4′′′), 128.7 (C-3′′′), 130.3 (C-1′′), 131.1 (C-1′), 137.2
(C-1′′′), 147.2 (C-4′), 148.2 (C-4′′), 149.3 (C-3′′), 150.0 (C-3′), 177.8 (C-2). IR: νMAX (film)/cm−1; 3523
(br), 2935, 1761, 1514, 1261, 1025, 911, 730. HRMS (ESI+) Found [M + Na]+ 515.2023; C29H32NaO7
requires 515.2040.
(3R*,4R*,5S*)-4-(3′′,4′′-Dimethoxybenzyl)-3-(4′-hydroxy-3′-methoxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4ae). Using general procedure F: Benzyl ether 4ad (0.27 g, 0.55 mmol) gave the title
compound 4ae (0.19 g, 88%) as a yellow solid. Rf = 0.43 (19:1 CH2Cl2, methanol). Melting point:
183–185 ◦C. δH (400 MHz; CDCl3) 1.63 (1H, t, J = 6.5 Hz, 6-OH), 2.34–2.43 (1H, m, 4-H), 2.53 (1H, dd,
J = 13.8, 8.1 Hz, 7′′-HA), 2.62 (1H, dd, J = 13.8, 6.1 Hz, 7′′-HB), 2.69 (1H, dt, J = 9.5, 6.0 Hz, 3-H), 2.92
(2H, d, J = 6.0 Hz, 7′-H), 3.13 (1H, ddd, J = 12.5, 6.5, 5.3 Hz, 6-HA), 3.51 (1H, ddd, J = 12.5, 6.5, 2.5 Hz,
6-HB), 3.82 (3H, s, 3′-OCH3), 3.84 (3H, s, 3′′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J = 8.0, 5.3,
2.5 Hz, 5-H), 5.52 (1H, s, 4′-OH), 6.46 (1H, d, J = 2.0 Hz, 2′′-H), 6.57 (1H, dd, J = 8.1, 2.0 Hz, 6′′-H), 6.63
(1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.66 (1H, d, J = 1.9 Hz, 2′-H), 6.76 (1H, d, J = 8.1 Hz, 5′′-H), 6.83 (1H,
d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.1 (C-7′), 38.6 (C-7′′), 41.6 (C-4), 47.7 (C-3), 56.0, 56.1 (3′,
3′′, 4′′-OCH3), 63.4 (C-6), 84.1 (C-5), 111.5 (C-5′′), 111.9 (C-2′), 112.1 (C-2′′), 114.4 (C-5′), 121.0 (C-6′′),
122.3 (C-6′), 129.7 (C-1′), 130.4 (C-1′′), 144.7 (C-4′), 146.8 (C-3′), 148.2 (C-4′′), 149.3 (C-3′′), 177.8 (C-2).
IR: νMAX (film)/cm−1; 3438 (br), 2937, 1755, 1514, 1236, 1155, 1025, 907, 723. HRMS (ESI+) Found
[M + Na]+ 425.1564; C22H26NaO7 requires 425.1571.
(3R*,4R*)-3,4-bis(3′,4′-Methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (4bb). Using
general procedure B: Morpholine amide 35bb (0.322 g, 0.74 mmol) in tBuOH/H2O/THF and a reaction
time of 5 days. The crude product was then purified by column chromatography (2:1 hexanes, ethyl
acetate) to give the title compound 4bb (0.145 g, 51%) as a pale-yellow oil.
Rf = 0.59 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.72 (1H, br, 6-OH), 2.32–2.41 (1H, m, 4-H),
2.47 (1H, dd, J = 13.7, 8.1 Hz, 7′′-HA), 2.56 (1H, dd, J = 13.7, 6.2 Hz, 7′′-HB), 2.65 (1H, ddd, J = 9.0, 7.5,
5.3 Hz, 3-H), 2.85 (1H, dd, J = 14.0, 7.5 Hz, 7′-HA), 2.96 (1H, dd, J = 14.0, 5.3 Hz, 7′-HB), 3.15 (1H, dd,
J = 12.6, 4.9 Hz, 6-HA), 3.54 (1H, dd, J = 12.6, 2.5 Hz, 6-HB), 4.18 (1H, ddd, J = 7.7, 4.9, 2.5 Hz, 5-H),
5.93–5.95 (4H, m, 2 × OCH2O), 6.45–6.49 (2H, m, 2′′, 6′′-H), 6.60 (1H, dd, J = 7.8, 1.7 Hz, 6′-H), 6.63 (1H,
d, J = 1.7 Hz, 2′-H), 6.70 (1H, d, J = 7.8 Hz, 5′′-H), 6.73 (1H, d, J = 7.8 Hz, 5′-H). δC (100 MHz; CDCl3)
35.4 (C-7′), 38.9 (C-7′′), 41.8 (C-4), 47.6 (C-3), 63.3 (C-6), 83.9 (C-5), 101.1, 101.2 (2 × OCH2O), 108.4
(C-5′), 108.6 (C-5′′), 109.2 (C-2′′), 109.6 (C-2′), 121.9 (C-6′′), 122.4 (C-6′), 131.5 (C-1′, 1′′), 146.6 (C-4′, 4′′),
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148.0, 148.1 (C-3′, 3′′), 177.6 (C-2). IR: νMAX (film)/cm−1; 3432 (br), 2922, 1760, 1503, 1490, 1444, 1247,
1038, 927, 811. HRMS (ESI+) Found [M + H]+ 385.1279; C21H21O7 requires 385.1282.
(3R*,4R*)-3-(3′,4′-Dimethoxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4ba). Using general procedure B: Morpholine amide 35ba (0.336 g, 0.74 mmol) in tBuOH/H2O/
THF and a reaction time of 4 days. The crude product was then purified by column chromatography
(1:3 hexanes, ethyl acetate) to give the title compound 4ba (0.103 g, 34%) as a pale yellow oil.
Rf = 0.48 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.68 (1H, t, J = 6.6 Hz, 6-OH), 2.33–2.42
(1H, m, 4-H), 2.48 (1H, dd, J = 13.7, 7.9 Hz, 7′′-HA), 2.56 (1H, dd, J = 13.7, 6.3 Hz, 7′′-HB), 2.68 (1H, ddd,
J = 9.3, 6.9, 5.4 Hz, 3-H), 2.89 (1H, dd, J = 14.0, 6.9 Hz, 7′-HA), 2.96 (1H, dd, J = 14.0, 5.4 Hz, 7′-HB), 3.15
(1H, ddd, J = 12.5, 6.6, 5.2 Hz, 6-HA), 3.52 (1H, ddd, J = 12.5, 6.6, 2.6 Hz, 6-HB), 3.85 (3H, s, 3′-OCH3),
3.86 (3H, s, 4′-OCH3), 4.18 (1H, ddd, J = 7.9, 5.2, 2.6 Hz, 5-H), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H,
d, J = 1.4 Hz, OCHBO), 6.44 (1H, d, J = 1.6 Hz, 2′′-H), 6.47 (1H, dd, J = 7.8, 1.6 Hz, 6′′-H), 6.67 (1H, d, J =
2.2 Hz, 2′-H), 6.68–6.72 (2H, m, 6′, 5′′-H), 6.79 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.2 (C-7′),
38.8 (C-7′′), 41.7 (C-4), 47.6 (C-3), 56.0 (3′, 4′-OCH3), 63.4 (C-6), 83.8 (C-5), 101.3 (OCH2O), 108.5 (C-5′),
109.2 (C-2′′), 111.3 (C-5′′), 112.5 (C-2′), 121.6 (C-6′), 121.9 (C-6′′), 130.3 (C-1′), 131.5 (C-1′′), 146.7 (C-4′′),
148.1 (C-4′, 3′′), 149.2 (C-3′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3472 (br), 2933, 1760, 1516, 1490, 1242,
1157, 1028, 925, 810, 730. HRMS (ESI+) Found [M + Na]+ 423.1423; C22H24NaO7 requires 423.1414.
(3R*,4R*)-3-(3′,4′,5′-Trimethoxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4bc). Using general procedure B: Morpholine amide 35bc (0.372 g, 0.77 mmol) in tBuOH/H2O/THF
and a reaction time of 4 days. The crude product was then purified by column chromatography (1:3
hexanes, ethyl acetate) to give the title compound 4bc (0.084 g, 25%) as a pale-yellow oil.
Rf = 0.38 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.69 (1H, t, J = 6.6 Hz, 6-OH), 2.36–2.45 (1H,
m, 4-H), 2.53 (1H, dd, J = 13.8, 7.6 Hz, 7′′-HA), 2.59 (1H, dd, J = 13.8, 6.8 Hz, 7′′-HB), 2.70 (1H, ddd, J =
9.5, 6.7, 5.4 Hz, 3-H), 2.87 (1H, dd, J = 14.0, 6.7 Hz, 7′-HA), 2.93 (1H, dd, J = 14.0, 5.4 Hz, 7′-HB), 3.22
(1H, ddd, J = 12.7, 6.6, 5.0 Hz, 6-HA), 3.58 (1H, ddd, J = 12.7, 6.6, 2.5 Hz, 6-HB), 3.82 (3H, s, 4′-OCH3),
3.84 (6H, s, 3′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J = 7.9, 5.0, 2.5 Hz, 5-H), 5.94 (1H, d, J =
1.4 Hz, OCHAO), 5.94 (1H, d, J = 1.4 Hz, OCHBO), 6.37 (2H, s, 2′-H), 6.46 (1H, d, J = 1.8 Hz, 2′′-H),
6.48 (1H, dd, J = 7.9, 1.8 Hz, 6′′-H), 6.70 (1H, d, J = 7.9 Hz, 5′′-H). δC (100 MHz; CDCl3) 36.0 (C-7′),
38.8 (C-7′′), 41.9 (C-4), 47.6 (C-3), 56.3 (3′-OCH3), 61.1 (4′-OCH3), 63.3 (C-6), 83.8 (C-5), 101.3 (OCH2O),
106.5 (C-2′), 108.5 (C-5′′), 109.2 (C-2′′), 121.9 (C-6′′), 131.4 (C-1′′), 133.6 (C-1′), 137.1 (C-4′), 146.7 (C-4′′),
148.2 (C-3′′), 153.5 (C-3′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3475 (br), 2941, 1760, 1591, 1490, 1445,
1244, 1127, 1036, 926. HRMS (ESI+) Found [M + Na]+ 453.1519; C23H26NaO8 requires 453.1520.
(3R*,4R*)-3-(3′-Methoxy-4′-benzyloxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4bd). Using general procedure B: Morpholine amide 35bd (0.405 g, 0.77 mmol) in tBuOH/H2O/
THF and a reaction time of 5 days. The crude product was then purified by column chromatography (1:3
hexanes, ethyl acetate) to give the title compound 4bd (0.205 g, 56%) as a pale-yellow oil.
Rf = 0.58 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.64 (1H, t, J = 6.6 Hz, 6-OH), 2.31–2.40 (1H,
m, 4-H), 2.46 (1H, dd, J = 13.7, 7.9 Hz, 7′′-HA), 2.53 (1H, dd, J = 13.7, 6.3 Hz, 7′′-HB), 2.67 (1H, ddd, J =
9.2, 7.2, 5.3 Hz, 3-H), 2.87 (1H, dd, J = 14.0, 7.2 Hz, 7′-HA), 2.95 (1H, dd, J = 14.0, 5.3 Hz, 7′-HB), 3.13
(1H, ddd, J = 12.6, 6.6, 5.1 Hz, 6-HA), 3.48 (1H, ddd, J = 12.6, 6.6, 2.6 Hz, 6-HB), 3.86 (3H, s, 3′-OCH3),
4.17 (1H, ddd, J = 7.8, 5.1, 2.6 Hz, 5-H), 5.13 (2H, s, 7′′′-H), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H, d,
J = 1.4 Hz, OCHBO), 6.43 (1H, d, J = 1.6 Hz, 2′′-H), 6.45 (1H, dd, J = 7.9, 1.6 Hz, 6′′-H), 6.64 (1H, dd, J =
8.2, 2.0 Hz, 6′-H), 6.68–6.70 (2H, m, 2′, 5′′-H), 6.81 (1H, d, J = 8.2 Hz, 5′-H), 7.27–7.30 (1H, m, 4′′′-H),
7.32–7.36 (2H, m, 3′′′-H), 7.40–7.44 (2H, m, 2′′′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.8 (C-7′′), 41.8
(C-4), 47.6 (C-3), 56.1 (3′-OCH3), 63.4 (C-6), 71.3 (C-7′′′), 83.8 (C-5), 101.3 (OCH2O), 108.5 (C-5′′), 109.2
(C-2′′), 113.0 (C-2′), 114.4 (C-5′), 121.5 (C-6′), 121.9 (C-6′′), 127.5 (C-2′′′), 128.0 (C-4′′′), 128.7 (C-3′′′),
131.0 (C-1′), 131.5 (C-1′′), 137.3 (C-1′′′), 146.7 (C-4′′), 147.2 (C-4′), 148.1 (C-3′′), 150.0 (C-3′), 177.7 (C-2).
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IR: νMAX (film)/cm−1; 3471 (br), 2940, 1743, 1504, 1490, 1366, 1230, 1036, 926, 735. HRMS (ESI+) Found
[M + Na]+ 499.1729; C28H28NaO7 requires 499.1727.
(3R*,4R*,5S*)-4-(3′′,4′′-Methylenedioxybenzyl)-3-(4′-hydroxy-3′-methoxybenzyl)-5-(hydroxymethyl)
dihydrofuran-2(3H)-one (4be). Using general procedure F: Benzyl ether 4bd (0.02 g, 0.04 mmol) and
a reaction time of 1 h. The crude product was then purified by column chromatography (1:3 hexanes,
ethyl acetate) to give the title compound 4be (0.017 g, quant.) as a colourless oil. Rf = 0.52 (1:3 hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 1.74 (1H, br, 6-OH), 2.33–2.42 (1H, m, 4-H), 2.48 (1H, dd, J = 13.7,
8.0 Hz, 7′′-HA), 2.57 (1H, dd, J = 13.7, 6.2 Hz, 7′′-HB), 2.67 (1H, ddd, J = 9.4, 6.9, 5.5 Hz, 3-H), 2.88 (1H,
dd, J = 14.0, 6.9 Hz, 7′-HA), 2.94 (1H, dd, J = 14.0, 5.5 Hz, 7′-HB), 3.15 (1H, br d, J = 12.6 Hz, 6-HA), 3.52
(1H, br d, J = 12.6 Hz, 6-HB), 3.86 (3H, s, 3′-OCH3), 4.18 (1H, ddd, J = 8.0, 5.0, 2.5 Hz, 5-H), 5.54 (1H,
s, 4′-OH), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H, d, J = 1.4 Hz, OCHBO), 6.45 (1H, d, J = 1.9 Hz,
2′′-H), 6.47 (1H, dd, J = 7.7, 1.9 Hz, 6′′-H), 6.63 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.67 (1H, d, J = 1.9 Hz,
2′-H), 6.70 (1H, d, J = 7.7 Hz, 5′′-H), 6.84 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.8
(C-7′′), 41.7 (C-4), 47.7 (C-3), 56.1 (3′-OCH3), 63.4 (C-6), 83.9 (C-5), 101.3 (OCH2O), 108.6 (C-5′′), 109.2
(C-2′′), 111.8 (C-2′), 114.5 (C-5′), 121.9 (C-6′′), 122.3 (C-6′), 129.6 (C-1′), 131.5 (C-1′′), 144.7 (C-4′), 146.7
(C-3′), 146.8 (C-4′′), 148.1 (C-3′′), 177.8 (C-2). IR: νMAX (film)/cm −1; 3449 (br), 2933, 1754, 1516, 1490,
1246, 1036, 926, 812. HRMS (ESI+) Found [M + Na]+ 409.1246; C21H22NaO7 requires 409.1258.
(±)-Arcitin (1aa). Using general procedure C: Lactone 4aa (0.16 g, 0.39 mmol) and a reaction time of
2 h to give triol 38aa (0.17 g, quant.) as a colourless oil. Then using general procedure D: Triol 38aa
(0.16 g, 0.37 mmol) and a reaction time of 2.5 h to give lactol 39aa (0.14 g, 97%) which was used without
further purification. Then using general procedure E: Lactol 39aa (0.054 g, 0.14 mmol) and a reaction
time of 3 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl acetate) to
give the title compound 1aa (0.05 g, 88%) as a pale yellow amorphous solid. Rf = 0.45 (19:1, CH2Cl2,
methanol). Melting point: 114–116 ◦C [lit. [49] 113 ◦C]. δH (400 MHz; CDCl3) 2.45–2.68 (4H, m, 8, 7′,
8′-H), 2.92 (1H, dd, J = 14.3, 6.8 Hz, 7-HA), 2.97 (1H, dd, J = 14.3, 5.5 Hz, 7-HB), 3.82 (3H, s, 3′-OCH3),
3.83 (3H, s, 3-OCH3), 3.85–3.90 (7H, m, 4, 4′-OCH3, 9′-HA), 4.13 (1H, t, J = 7.0 Hz, 9′-HB), 6.49 (1H,
d, J = 1.9 Hz, 2′-H), 6.55 (1H, dd, J = 8.1, 1.9 Hz, 6′-H), 6.66 (1H, dd, J = 8.1, 1.9 Hz, 6-H), 6.69 (1H, d,
J = 1.9 Hz, 2-H), 6.75 (1H, d, J = 8.1 Hz, 5-H), 6.77 (1H, d, J = 8.1 Hz, 5′-H). δC (100 MHz; CDCl3) 34.5
(C-7), 38.2 (C-7′), 41.1 (C-8′), 46.6 (C-8), 55.8, 55.9 (3, 4, 3′, 4′-OCH3), 71.2 (C-9′), 111.1 (C-5), 111.4 (C-5′),
111.9 (C-2′), 112.4 (C-2), 120.6 (C-6′), 121.4 (C-6), 130.2 (C-1), 130.5 (C-1′), 147.9 (C-4′), 148.0 (C-4), 149.1
(C-3, 3′), 178.7 (C-9). IR: νMAX (film)/cm−1; 2956, 1753, 1588, 1513, 1257, 1236, 1153, 1137, 1019, 825,
764. HRMS (ESI+) Found [M + H]+ 387.1806; C22H27O6 requires 387.1802. Values are in agreement
with literature data [50].
(±)-Bursehernin (1a). Using general procedure C: Lactone 4ab (0.114 g, 0.28 mmol) and a reaction
time of 30 min to give triol 38ab (0.111 g, 97%) as a cloudy oil. Then using general procedure D: Triol
38ab (0.111 g, 0.27 mmol) and a reaction time of 1 h to give lactol 39ab (0.093 g, 91%) which was used
without further purification. Then using general procedure E: Lactol 39ab (0.093 g, 0.25 mmol) and
a reaction time of 2 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl
acetate) to give the title compound 1ab (0.06 g, 65%) as a pale-yellow oil. Rf = 0.66 (19:1, CH2Cl2,
methanol). δH (400 MHz; CDCl3) 2.41–2.62 (4H, m, 8, 7′, 8′-H), 2.88 (1H, dd, J = 14.0, 6.9 Hz, 7-HA),
2.96 (1H, dd, J = 14.0, 5.1 Hz, 7-HB), 3.82 (3H, s, 3-OCH3), 3.83–3.86 (4H, m, 4-OCH3, 9′-HA), 4.10 (1H,
dd, J = 9.1, 6.9 Hz, 9′-HB), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO), 6.42 (1H,
d, J = 1.5 Hz, 2′-H), 6.44 (1H, dd, J = 7.9, 1.5 Hz, 6′-H), 6.66 (1H, d, J = 1.9 Hz, 2-H), 6.67–6.70 (2H, m, 6,
5′-H), 6.78 (1H, d, J = 8.0 Hz, 5-H). δC (100 MHz; CDCl3) 34.7 (C-7), 38.4 (C-7′), 41.2 (C-8′), 46.6 (C-8),
55.9 (3, 4-OCH3), 71.2 (C-9′), 101.1 (OCH2O), 108.4 (C-5′), 108.8 (C-2′), 111.2 (C-5), 112.3 (C-2), 121.4
(C-6), 121.6 (C-6′), 130.2 (C-1), 131.7 (C-1′), 146.4 (C-4′), 148.0 (C-3′), 148.1 (C-4), 149.2 (C-3), 178.7 (C-9).
IR: νMAX (film)/cm−1; 2907, 1764, 1514, 1489, 1442, 1240, 1025, 923, 808, 730. HRMS (ESI+) Found
[M + Na]+ 393.1317; C21H22NaO6 requires 393.1309. Values are in agreement with literature data [51].
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(±)-4-O-Methyl traxillagenin (1ac). Using general procedure C: Lactone 4ac (0.119 g, 0.27 mmol) and
a reaction time of 45 min to give triol 38ac (0.11 g, 90%) as a cloudy oil. The using general procedure
D: Triol 38ac (0.11 g, 0.24 mmol) and a reaction time of 15 min. The crude product was purified by
column chromatography (1:2 hexanes, ethyl acetate) to give lactol 39ac (0.06 g, 60%) as a colourless oil.
Then using general procedure E: Lactol 39ac (0.06 g, 0.15 mmol) and a reaction time of 3 h. The crude
product purified by column chromatography (1:1, hexanes, ethyl acetate) to give the title compound
1ac (0.044 g, 73%) as a white solid. Rf = 0.61 (19:1, CH2Cl2, methanol). Melting point: 126 ◦C. δH
(400 MHz; CDCl3) 2.44–2.66 (4H, m, 8, 7′, 8′-H), 2.91 (1H, dd, J = 14.1, 6.6 Hz, 7-HA), 2.98 (1H, dd,
J = 14.1, 5.4 Hz, 7-HB), 3.79 (6H, s, 3′-OCH3), 3.80 (6H, s, 4′-OCH3), 3.83 (3H, s, 3-OCH3), 3.84 (3H, s,
4-OCH3), 3.87 (1H, dd, J = 9.2, 7.3 Hz, 9′-HA), 4.14 (1H, dd, J = 9.2, 7.0 Hz, 9′-HB), 6.19 (2H, s, 2′-H), 6.63
(1H, dd, J = 8.0, 2.0 Hz, 6-H), 6.70 (1H, d, J = 2.0 Hz, 2-H), 6.75 (1H, d, J = 8.0 Hz, 5-H). δC (100 MHz;
CDCl3) 34.6 (C-7), 39.0 (C-7′), 41.2 (C-8′), 46.7 (C-8), 56.0 (3, 4-OCH3), 56.2 (3′-OCH3), 60.9 (4′-OCH3),
71.3 (C-9′), 105.7 (C-2′), 111.2 (C-5), 112.6 (C-2), 121.4 (C-6), 130.3 (C-1), 133.8 (C-1′), 137.0 (C-4′), 148.1
(C-4), 149.2 (C-3), 153.5 (C-3′), 178.7 (C-9). IR: νMAX (film)/cm−1; 2938, 1764, 1590, 1509, 1460, 1237,
1123, 1014, 731. HRMS (ESI+) Found [M + Na]+ 439.1716; C23H28NaO7 requires 439.1727. Values are in
agreement with literature data [52].
(±)-4′-O-Benzyl buplerol (1ad). Using general procedure C: Lactone 4ad (0.505 g, 1.02 mmol) and
a reaction time of 3 h to give the triol 38ad (0.472 g, 93%) as a cloudy oil. Then using general procedure
D: Triol 38ad (0.472 g, 0.95 mmol) and a reaction time of 30 min to give lactol 39ad (0.416 g, 94%)
as a white solid which was used without further purification. Then using general procedure E:
Lactol 39ad (0.416 g, 0.90 mmol) and a reaction time of 1.5 h. The crude product was purified by
column chromatography (1:1, hexanes, ethyl acetate) to give the title compound 1ad (0.374 g, 90%) as
a pale-yellow oil. Rf = 0.52 (1:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.42–2.66 (4H, m, 8, 7′,
8′-H), 2.91 (1H, dd, J = 14.1, 6.2 Hz, 7-HA), 2.95 (1H, dd, J = 14.1, 5.7 Hz, 7-HB), 3.827, 3.829 (6H, 2 × s,
3, 3′-OCH3), 3.85 (3H, s, 4-OCH3), 3.83–3.88 (1H, m, 9′-HA), 4.11 (1H, dd, J = 8.7, 7.0 Hz, 9′-HB), 5.12
(2H, s, Ph-CH2), 6.48 (1H, dd, J = 8.0, 2.0 Hz, 6′-H), 6.51 (1H, d, J = 2.0 Hz, 2′-H), 6.64 (1H, dd, J = 8.2,
2.0 Hz, 6-H), 6.68 (1H, d, J = 2.0 Hz, 2-H), 6.76 (1H, d, J = 8.2 Hz, 5-H), 6.77 (1H, d, J = 8.0 Hz, 5′-H),
7.27–7.32 (1H, m, Ph-p-H), 7.33–7.38 (2H, m, Ph-m-H), 7.40–7.44 (2H, m, Ph-o-H). δC (100 MHz; CDCl3)
34.6 (C-7), 38.3 (C-7′), 41.2 (C-8′), 46.7 (C-8), 56.0 (3, 3′-OCH3), 56.1 (4-OCH3), 71.3, 71.4 (C-9′, Ph-CH2),
111.3 (C-5), 112.5 (C-2), 112.6 (C-5′), 114.5 (C-5′), 120.7 (C-6′), 121.5 (C-6), 127.4 (Ph-o-C), 128.0 (Ph-p-C),
128.7 (Ph-m-C), 130.3 (C-1), 131.3 (C-1′), 137.3 (Ph-i-C), 147.2 (C-4′), 148.1 (C-4), 149.2 (C-3), 149.9 (C-3′),
178.8 (C-9). IR: νMAX (film)/cm−1; 2935, 1763, 1512, 1260, 1233, 1140, 1014, 736, 697. HRMS (ESI+)
Found [M + Na]+ 485.1934; C28H30NaO6 requires 485.1935.
(±)-Buplerol (1ae). Using general procedure F: Lactone 1ad (0.336 g, 0.73 mmol) and a reaction time of
3.5 h to give the title compound 1ae (0.271 g, quant.) as a white solid. Rf = 0.33 (1:1, hexanes, ethyl
acetate). Melting point: 101–103 ◦C. δH (400 MHz; CDCl3) 2.42–2.66 (4H, m, 8, 7′, 8′-H), 2.90 (1H, dd,
J = 14.1, 6.8 Hz, 7-HA), 2.97 (1H, dd, J = 14.1, 5.3 Hz, 7-HB), 3.81 (3H, s, 3-OCH3), 3.83 (3H, s, 3′-OCH3),
3.86 (4H, m, 4-OCH3), 3.87 (1H, dd, J = 8.9, 7.1 Hz, 9′-HA), 4.13 (1H, dd, J = 9.3, 7.1 Hz, 9′-HB), 5.51 (1H,
s, 4′-OH), 6.43 (1H, d, J = 1.9 Hz, 2′-H), 6.52 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.64–6.67 (2H, m, 2, 6-H), 6.77
(1H, d, J = 8.6 Hz, 5-H), 6.80 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 34.7 (C-7), 38.5 (C-7′), 41.3
(C-8′), 46.7 (C-8), 55.9, 56.0 (3, 3′, 4-OCH3), 71.4 (C-9′), 111.1, 111.2 (C-5, 5′), 112.5 (C-2), 114.6 (C-2′),
121.5 (C-6, 6′), 129.9 (C-1′), 130.4 (C-1), 144.6 (C-4′), 146.7 (C-3′), 148.1 (C-4), 149.2 (C-3), 178.9 (C-9). IR:
νMAX (film)/cm−1; 3417, 2938, 1760, 1513, 1236, 1148, 1023, 812, 795. HRMS (ESI+) Found [M + Na]+
395.1462; C21H24NaO6 requires 395.1465. Values are in agreement with literature data [53].
(±)-Kusunokinin (1ba). Using general procedure C: Lactone 4ba (0.082 g, 0.20 mmol) and a reaction
time of 1 h to give the triol 38ba (0.083 g, quant.) as a cloudy oil. Then using general procedure D: Triol
38ba (0.083 g, 0.20 mmol) and a reaction time of 15 min to give lactol 39ba (0.064 g, 84%) which was
used without further purification. Then using general procedure E: Lactol 39ba (0.056 g, 0.15 mmol)
and a reaction time of 1 h. The crude product was purified by column chromatography (2:1, hexanes,
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ethyl acetate) to give the title compound 1ba (0.051 g, 91%) as a colourless oil. Rf = 0.48 (1:1, hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 2.44–2.65 (4H, m, 8, 7′, 8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA),
2.95 (1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.82 (3H, s, 3′-OCH3), 3.85 (3H, s, 4′-OCH3), 3.87 (1H, dd, J =
9.2, 7.2 Hz, 9′-HA), 4.14 (1H, dd, J = 9.2, 7.0 Hz, 9′-HB), 5.92 (1H, d, J = 1.4 Hz, OCHAO), 5.93 (1H, d,
J = 1.4 Hz, OCHBO), 6.48 (1H, d, J = 2.0 Hz, 2′-H), 6.55–6.60 (3H, m, 2, 6, 6′-H), 6.71 (1H, d, J = 7.7 Hz,
5-H), 6.76 (1H, d, J = 8.2 Hz, 5′-H). δC (100 MHz; CDCl3) 34.9 (C-7), 38.4 (C-7′), 41.3 (C-8′), 46.6 (C-8),
55.9 (3′-OCH3), 56.0 (4′-OCH3), 71.4 (C-9′), 101.1 (OCH2O), 108.3 (C-5), 109.6 (C-2), 111.4 (C-5′), 111.8
(C-2′), 120.8 (C-6′), 122.4 (C-6), 130.6 (C-1′), 131.5 (C-1), 146.6 (C-4), 148.0 (C-3, 4′), 149.2 (C-3′), 178.6
(C-9). IR: νMAX (film)/cm−1; 2908, 1764, 1515, 1489, 1442, 1242, 1024, 912, 809, 729. HRMS (ESI+) Found
[M + Na]+ 393.1301; C21H22NaO6 requires 393.1309. Values are in agreement with literature data [50].
(±)-Hinokinin (1bb). Using general procedure C: Lactone 4bb (0.12 g, 0.31 mmol) and a reaction time
of 30 min to give the triol 38bb (0.12 g, quant.) as a cloudy oil. Then using general procedure D:
Triol 38bb (0.121 g, 0.31 mmol) and a reaction time of 10 min to give lactol 39bb (0.096 g, 86%) which
was used without further purification. Then using general procedure E: Lactol 39bb (0.089 g, 0.25
mmol) and a reaction time of 1 h. The crude product was purified by column chromatography (1:1,
hexanes, ethyl acetate) to give the title compound 1bb (0.08 g, 90%) as a pale-yellow oil. Rf = 0.73 (1:1,
hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.41–2.62 (4H, m, 8, 7′, 8′-H), 2.83 (1H, dd, J = 14.1, 7.2
Hz, 7-HA), 2.98 (1H, dd, J = 14.1, 5.0 Hz, 7-HB), 3.85 (1H, dd, J = 9.2, 7.1 Hz, 9′-HA), 4.12 (1H, dd, J =
9.2, 6.9 Hz, 9′-HB), 5.91–5.94 (4H, m, 2 × OCH2O), 6.44–6.47 (2H, m, 2′, 6′-H), 6.59 (1H, dd, J = 7.9,
1.8 Hz, 6-H), 6.62 (1H, d, J = 1.8 Hz, 2-H), 6.69 (1H, d, J = 8.4 Hz, 5′-H), 6.72 (1H, d, J = 7.9 Hz, 5-H). δC
(100 MHz; CDCl3) 34.9 (C-7), 38.4 (C-7′), 41.4 (C-8′), 46.6 (C-8), 71.2 (C-9′), 101.1 (2 × OCH2O), 108.4
(C-5, 5′), 108.9 (C-2′), 109.5 (C-2), 121.6 (C-6′), 122.3 (C-6), 131.5 (C-1), 131.7 (C-1′), 146.4 (C-4), 146.6
(C-4′), 148.0 (C-3, 3′), 178.5 (C-9). IR: νMAX (film)/cm−1; 2901, 1764, 1488, 1441, 1242, 1015, 924, 808,
728. HRMS (ESI+) Found [M + Na]+ 377.0986; C20H18NaO6 requires 377.0996. Values are in agreement
with literature data [54].
(±)-Isoyatein (1bc). Using general procedure C: Lactone 4bc (0.076 g, 0.18 mmol) and a reaction time
of 1 h to give the triol 38bc (0.077 g, >99%) as a cloudy oil. Then using general procedure D: Triol
38bc (0.077 g, 0.18 mmol) and a reaction time of 1 h to give lactol 39bc (0.057 g, 80%) which was used
without further purification. Then using general procedure E: Lactol 39bc (0.05 g, 0.12 mmol) and
a reaction time of 3 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl
acetate) to give the title compound 1bc (0.8 mg, 16%) as a pale-yellow oil. Rf = 0.55 (1:1, hexanes, ethyl
acetate). δH (400 MHz; CDCl3) 2.46–2.64 (4H, m, 8, 7′, 8′-H), 2.86 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.98
(1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.81 (6H, s, 3′-OCH3), 3.82 (3H, s, 4′-OCH3), 3.89 (1H, dd, J = 9.2, 7.0 Hz,
9′-HA), 4.19 (1H, dd, J = 9.2, 6.8 Hz, 9′-HB), 5.93 (1H, d, J = 1.5 Hz, OCHAO), 5.94 (1H, d, J = 1.5 Hz,
OCHBO), 6.20 (2H, s, 2′-H), 6.58 (1H, dd, J = 7.9, 1.8 Hz, 6-H), 6.61 (1H, d, J = 1.8 Hz, 2-H), 6.71 (1H,
d, J = 7.9 Hz, 5-H). δC (100 MHz; CDCl3) 34.9 (C-7), 39.2 (C-7′), 41.4 (C-8′), 46.6 (C-8), 56.2 (3′-OCH3),
61.0 (4′-OCH3), 71.4 (C-9′), 101.2 (OCH2O), 105.7 (C-2′), 108.3 (C-5), 109.6 (C-2), 122.4 (C-6), 131.5
(C-1), 133.8 (C-1′), 137.0 (C-4′), 146.7 (C-4), 148.1 (C-3), 153.5 (C-3′), 178.5 (C-9). IR: νMAX (film)/cm−1;
2938, 1763, 1590, 1489, 1443, 1241, 1122, 1011, 927, 813, 732. HRMS (ESI+) Found [M + Na]+ 423.1400;
C22H24NaO7 requires 423.1414. Values are in agreement with literature data [55].
(±)-4′-O-Benzyl haplomyrfolin (1bd). Using general procedure C: Lactone 4bd (0.18 g, 0.38 mmol) and
a reaction time of 20 min to give the triol 38bd (0.18 g, quant.) as a cloudy oil. Then using general
procedure D: Triol 38bd (0.18 g, 0.38 mmol) and a reaction time of 20 min to give lactol 39bd (0.13 g,
76%) as a white solid which was used without further purification. Then using general procedure
E: Lactol 39bd (0.13 g, 0.28 mmol) and a reaction time of 2 h. The crude product was purified by
column chromatography (3:1, hexanes, ethyl acetate) to give the title compound 1bd (0.12 g, 94%) as
a colourless oil. Rf = 0.65 (1:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.43–2.64 (4H, m, 8, 7′,
8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.94 (1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.83 (3H, s, 3′-OCH3),
3.87 (1H, dd, J = 9.1, 7.2 Hz, 9′-HA), 4.14 (1H, dd, J = 9.1, 7.0 Hz, 9′-HB), 5.12 (2H, s, 7′′-H), 5.91 (1H, d,
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J = 1.4 Hz, OCHAO), 5.93 (1H, d, J = 1.4 Hz, OCHBO), 6.49–6.52 (2H, m, 2′, 6′-H), 6.57 (1H, dd, J = 7.9,
1.8 Hz, 6-H), 6.59 (1H, d, J = 1.8 Hz, 2-H), 6.70 (1H, d, J = 7.9 Hz, 5-H), 6.78 (1H, d, J = 8.5 Hz, 5′-H),
7.27–7.32 (1H, m, 4′′-H), 7.33–7.38 (2H, m, 3′′-H), 7.41–7.45 (2H, m, 2′′-H). δC (100 MHz; CDCl3) 34.8
(C-7), 38.4 (C-7′), 41.3 (C-8′), 46.5 (C-8), 56.0 (3′-OCH3), 71.2 (C-7′′), 71.3 (C-9′), 101.1 (OCH2O), 108.3
(C-5), 109.6 (C-2), 112.4 (C-2′), 114.4 (C-5′), 120.7 (C-6′), 122.4 (C-6), 127.4 (C-2′′), 128.0 (C-4′′), 128.6
(C-3′′), 131.2 (C-1), 131.5 (C-1′), 137.2 (C-1′′), 146.6 (C-4), 147.1 (C-4′), 148.0 (C-3), 149.9 (C-3′), 178.6
(C-9). IR: νMAX (film)/cm−1; 2907, 1765, 1504, 1489, 1443, 1244, 1140, 1034, 911, 809, 730. HRMS (ESI+)
Found [M + Na]+ 469.1612; C27H26NaO6 requires 469.1622.
(±)-Haplomyrfolin (1be). Using general procedure F: Lactone 1bd (0.119 g, 0.27 mmol) and a reaction
time of 1.5 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 1be (0.086 g, 91%) as a colourless oil. Rf = 0.47 (1:1 hexanes, ethyl acetate).
δH (400 MHz; CDCl3) 2.43–2.63 (4H, m, 8, 7′, 8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.95 (1H, dd,
J = 14.1, 5.2 Hz, 7-HB), 3.83 (3H, s, 3′-OCH3), 3.86 (1H, dd, J = 9.1, 7.2 Hz, 9′-HA), 4.13 (1H, dd, J = 9.1,
7.0 Hz, 9′-HB), 5.63 (1H, s, 4′-OH), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO),
6.46 (1H, d, J = 1.9 Hz, 2′-H), 6.51 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.58 (1H, dd, J = 7.8, 1.7 Hz, 6-H), 6.60
(1H, d, J = 1.7 Hz, 2-H), 6.70 (1H, d, J = 7.8 Hz, 5-H), 6.80 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3)
34.8 (C-7), 38.3 (C-7′), 41.4 (C-8′), 46.5 (C-8), 55.9 (3′-OCH3), 71.3 (C-9′), 101.1 (OCH2O), 108.3 (C-5),
109.6 (C-2), 111.2 (C-2′), 114.6 (C-5′), 121.4 (C-6′), 122.4 (C-6), 129.9 (C-1′), 131.5 (C-1), 144.5 (C-4′), 146.5
(C-4), 146.7 (C-3′), 147.9 (C-3), 178.7 (C-9). IR: νMAX (film)/cm−1; 3468, 2921, 1762, 1515, 1489, 1443,
1243, 1035, 907, 725. HRMS (ESI+) Found [M + Na]+ 379.1151; C20H20NaO6 requires 379.1152. Values
are in agreement with literature data [56].
4. Biological Assay Methods
4.1. Cell Culture
Jurkat E61 cells (ECACC) were maintained at 37 ◦C in RMPI media (Lonza) supplemented with
10% Foetal Bovine Serum (FBS) (Lonza) (10% RPMI) in a humidified environment of 5% CO2 in air.
Cells were routinely passaged to maintain a cell density of between 1 × 105 and 1 × 106/mL.
4.2. Drug Treatments
Lignans were diluted to stock concentrations of 30 mM in DMSO and further diluted to the
working concentration in 10% RPMI. The DMSO diluted to the appropriate concentration was used as
the vehicle-control. Cells were seeded at the relevant density per well depending upon the assay to be
performed, in 100 µL volume of fresh 10% RPMI. Trypan blue exclusion method was used to assess
viability prior to experiments and cell viability was always >95%. Lignans were added at 100 µL/well
to the relevant wells. Cells were incubated at 37 ◦C in a humidified environment of 5% CO2 in air
for the indicated times. Dead cell controls were included in subsequent viability assays by treating
cells with 50 µL/well EtOH (final concentration 50%) for 48 h. Apoptotic controls were included in
subsequent apoptosis assays by exposing cells to a heat shock at 43 ◦C for 2 h. Positive controls for
cell cycle analysis were included by treating cells with 0.5 µM camptothecin for 4 h to induce cell
cycle arrest.
4.3. MTS Assay
Following treatments at a cell density of 1 × 105 cells/well, the samples were centrifuged at
500 g for 5 min and the supernatant was removed. A 100 µL/well volume of fresh 10 % RPMI was
added. A 20 µL volume of MTS solution (Promega, G1112) was added to each well and the plate
was incubated in the dark for 1 h at 37 ◦C. The absorbance was detected at 490 nm on a Synergy HT
plate reader.
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4.4. Annexin V/PI Assay
Following treatments at a cell density of 1 × 105 cells/well, the samples were centrifuged at 500 g
for 5 min and the supernatant was removed. Cells were washed in 500 µL DPBS before addition
of 100 µL of 1 × Annexin V binding buffer (BD Biosciences). A 5 µL volume of FITC-conjugated
Annexin V (BD Biosciences) and 10 µL Propidium Iodide (BD Biosciences) was added and the cells
were incubated in the dark for 20 min. Samples were diluted by addition of 400 µL 1 × Annexin
V binding buffer before immediate analysis on an Accuri C6 Flow Cytometer (Becton Dickinson,
Oxford, UK).
4.5. Cell Cycle Analysis
Following treatments at a cell density of 5 × 106/well, cells were centrifuged at 500 g for 5 min
and the supernatant was removed. The remaining cell pellet was vortexed while simultaneously
adding 500 µL of 70% ethanol dropwise, fixing the cells and minimising clumping. The samples were
incubated at 4 ◦C for 30 min, and then centrifuged at 1000 g for 5 min. The supernatant was discarded,
and the pellet was re-suspended in 500 µL DPBS. The samples were centrifuged again at 1000 g for
5 min, and the supernatant was removed a final time. The pellet was resuspended in 50 µL RNase
A (100 µg/mL stock; Roche, UK) and 200 µL PI (50 µg/mL stock; Sigma, UK). The samples were
analyzed on an Accuri C6 flow cytometer (Becton Dickinson) and data was modelled and interpreted
using ModFit Analysis Software, version 5.0 (Verity Software House).
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